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Abstract
The purpose of this quality improvement project was to determine if screening
primary care patients with psoriasis will improve early detection of celiac disease (CD),
rheumatoid arthritis, and Crohn’s disease (CrD). The aim of this project is to assess the
utility of early screening in patients with psoriasis in order to facilitate earlier diagnosis
of CD, RA and CrD, which would consequently initiate earlier treatment and improve
long-term patient outcomes. Genetic and population-based studies suggest that
individuals with psoriasis have a greater risk of also having CrD, CD or RA, than do
individuals without psoriasis. The literature also suggests that health care providers
would be prudent to evaluate psoriatic patients in a prospective manner for these AI
disorders in order to improve the patient’s long-term health outcomes.
Based on the literature, the DNP project investigator developed a nonpsychometric patient questionnaire to capture data including the signs and symptoms of
CD, CrD and RA and three referral algorithms (one each per CD, CrD and RA). Over
two weeks at a Northern Virginia dermatology clinic, the patient questionnaire was
delivered to 261 adult patients, of which 34 were identified as psoriatic or newly
diagnosed.
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Findings indicated 100% provider compliance documentation for all 34 patients
noting that the patient a) had been screened, and b) if referral was or was not indicated.
Frequency data indicated that the most reported symptom was a history of vitamin D
deficiency (38.24%). Thirty percent of psoriatic patients reported having a first-degree
relative with celiac disease, Crohn’s disease or rheumatoid arthritis. The most frequently
reported symptoms were for rheumatoid arthritis: daily joint or muscle pain > 6 weeks
(29.41%), daily tender or swollen joints > 6 weeks (23.53%), and weakness or fatigue > 6
weeks (23.53%). The most reported GI symptom was abdominal distention and/or
bloating after eating (14.71%). The least reported symptoms, at 2.94% each, were
abdominal pain after eating, painful bowel movements, and running a fever in the past 4
weeks. This quality improvement project highlights the need to evaluate adult patients
with psoriasis for polyautoimmunity and familial autoimmunity and is consistent with the
literature that recommends screening for these polyimmune relationships.
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Chapter 1
Background and Significance
1.1 Introduction
Autoimmune (AI) diseases refer to a collection of diseases where the immune
system mistakenly directs the body to attack its own healthy organs, tissues, and blood,
rather than the foreign organisms the immune response was designed to combat. The
result is impaired function of the targeted organ or system. The National Institute of
Health ([NIH], 2005) has identified more than 80 clinically distinct autoimmune
disorders, while the American Autoimmune Related Disease Association ([AARDA],
2011) recognizes greater than 100 known autoimmune diseases. Psoriasis, a chronic,
inflammatory skin disease, is known to be the most prevalent AI disease in humans
(Raychaudhuri, 2014), affecting approximately 2-5% of the world population and as
many as 7.5 million Americans (NIH, 2005).
Psoriasis belongs to a subset of AI diseases classified as Immune-Mediated
Inflammatory Diseases (IMIDs) (Rahman, Inman, El-Gabalawy & Krause, 2010). The
concept of IMIDs describes a group of seemingly unrelated clinical disorders that share
common inflammatory pathways. While all IMIDs are AI diseases, the reverse is not
also true; all AI diseases are not IMIDs. Central to the disease process in IMIDs is the
imbalance and dysregulation of cytokine production (Rahman et al., 2010; Kuek,

1

Hazleton & Astor, 2007; Williams & Meyers, 2002). Cytokines play a pivotal
role in normal immune function. When these molecules are inappropriately expressed,
chronic inflammatory conditions arise. Celiac Disease (CD), Rheumatoid Arthritis (RA)
and Crohn’s Disease (CrD) also belong to this subset.
Another relatively new concept in the autoimmune field is polyautoimmunity,
which is defined as the coexistence of more than one AI disease, or IMID, in a single
individual (Rojas-Villarraga, Amaya-Amaya, Rodriguez-Rodriguez, Mantilla, & Anaya,
2012; Anaya, 2014). Research suggests that individuals with one autoimmune disease
typically will develop an additional one or more separate, and distinct, autoimmune
diseases over the course of their lifetime (Cooper, Bynum & Somers, 2009). Recent
population-based studies, as well as studies that have identified common genes associated
with multiple AI disorders, lend credibility to this idea that polyautoimmunity is not
random, and that there is a true association between different AI disorders. Specifically,
studies suggest that individuals with psoriasis have a greater risk of also having another
IMID, such as CrD, CD or RA, than do individuals without psoriasis (Augustin, Reich,
Glaeske, Schaeffer & Radtke, 2010; Bhatia, Millsop, Debbanch, Koo, Linos & Liao,
2014; Birkenfeld, Dreiher, Weitzman & Cohen, 2009; Cohen, Dreiher & Birkenfeld,
2009; Damasiewicz-Bodzek & Wielkoszynski, 2008; Einarsdottir et al., 2009; Li, Han,
Chan & Qureshi, 2013; Makredes, Robinson, Bala & Kimball, 2009; Qui, Z., Zhang, X.
Qui, Zhou & Li, 2013; Radtke et al., 2015; Tsai et al., 2011; Tsoi et al., 2013; Wolf et al.,
2008; Wu, Nugyen, Poon & Herrington, 2012).
Although these advances in research have fostered a greater understanding of
autoimmunity in the health care community, AI diseases continue to be one of the most
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clinically difficult to recognize categories of disease. According to the AARDA (2011),
it can take patients an average of five years and four health care professionals to obtain a
correct diagnosis. Diagnostically, IMIDs remain a challenge for both patients and health
care providers. The initial presentation of symptoms may be vague and confused with
other disease processes (AARDA, 2011). Additionally, health care professional
education provides minimal training about AI diseases, contributing to a poor
understanding of autoimmunity among primary health care providers. As a result, despite
the proven genetic component in AI disease, health care practitioners do not typically
inquire whether patients have a personal or family history of autoimmune diseases, or
screen for additional autoimmune diseases in the autoimmune patient. Lastly, there are
very few standardized tests for many of the 80-100 AI diseases (AARDA, 2011). These
gaps of knowledge represent lost opportunity for the patient whose disease process
remains unchecked and whose associated AI co-morbidities also go unaddressed.
Despite the differences in heterogenic expression and clinical characteristics
among the IMIDs’ psoriasis, CrD, CD and RA, the shared genetic and pathophysiologic
mechanisms suggest a common origin, and as health care providers, it is imperative to
capitalize upon this information. The potential links between these diseases a) must not
be ignored and b) must be further studied. The purpose of this project is to conduct a
substantive review of the literature and conduct screening of primary care patients with
psoriasis to determine early detection of celiac disease, rheumatoid arthritis, and Crohn’s
disease.
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1.2 Scope of problem
Autoimmune diseases. Autoimmune diseases, to include the immune-mediated
inflammatory diseases, can affect virtually every site in the body, including the nervous,
gastrointestinal, and endocrine systems, as well as skin and other connective tissue, eyes,
blood and blood vessels. These diseases are chronic conditions, for which there currently
is no cure. Autoimmune and immune-mediated inflammatory diseases follow a
progressive path, with more end-organ destruction over the passage of time. Symptoms
tend to increase in severity as the disease progresses and as more tissue destruction
occurs (San Jose Functional Medicine, 2012). While many of these diseases have low
prevalence as a single occurring health disease, collectively autoimmune diseases are the
third most common category of disease in the United States after cancer and heart disease
(NIH, 2005) affecting approximately 5-8% of the population or approximately 23.5
million Americans. For reasons unknown, their prevalence is rising, while paradoxically,
they continue to remain under detected and under diagnosed (NIH, 2005; AARDA,
2011).
Early diagnosis and treatment is key to staving off disease progression and
improving patient outcomes. However, it is also recognized that there is often a delay in
diagnosis due to the fact that symptoms are often vague, misdiagnosed, and treated
symptomatically. The delay in diagnosis and treatment can unfortunately, lead to poorer
clinical outcomes associated with accrued joint and organ damage.
Researchers have been uncertain exactly what triggers an autoimmune response,
but certain modifiable and non-modifiable factors that play a role in autoimmunity have
been identified (AARDA, 2011; NIH, 2005). Modifiable factors include an individual’s
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genetic predisposition toward autoimmunity, while non-modifiable factors could be
anything from viruses, bacteria, medications, pollutants, or hormones. Autoimmune
disorders present disproportionately, and predominately, in the female population, are the
second highest cause of chronic disease (AARDA, 2011) and have been among the top
ten leading causes of death for women in every age group up to 64 years of age (NIH,
2005).
Incidence and Prevalence. In the United States alone, these AI diseases affect
approximately 5-8% of the population, or 14 to 23.5 million individuals (NIH, 2005).
However, the current data about the prevalence of these diseases in the United States is
misleading, since most autoimmune disorders are asymptomatic for years before a
clinical pattern emerges. Due to the silent nature of AI disease onset, one can logically
extrapolate that the true numbers of individuals with autoimmune disorders is actually
much higher than the statistics suggest. Many patients with AI disorders remain
undiagnosed and therefore, have simply not been included in the current numbers.
Furthermore, according to the AARDA (2011), the prevalence of autoimmune disorders
as reported by the National Institute of Health, 14 to 23.5 million individuals was quite
deflated, since the statistic only accounted for 24 of the 80 recognized autoimmune
diseases. The AARDA (2011) estimates that the actual number of individuals that have
autoimmune diseases is closer to 50 million.
There is no doubt that the actual burden of these autoimmune diseases to society,
and to individuals, is enormous. Individually, these chronic and progressively
deteriorating disorders have caused emotional and financial challenges associated with
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lost productivity; decreased quality of life; co-morbid mental illnesses, particularly
depression and anxiety; and the disruption of social and family structures (NIH, 2002).
Costs. Quantifying the societal cost burden of AI disease has proven to be a
problematic task, as well. AARDA (2011) and NIH (2002) both agree that the lack of
epidemiological data on autoimmune disorders has made it difficult to calculate the full
direct and indirect cost to the overall health care system due to autoimmune disease. In
2001, the National Institutes of Allergy and Infectious Diseases (NIAID) Director, Dr.
Anthony Fauci estimated that annual autoimmune disease treatment costs were greater
than $100 billion. Again, this number most likely underrepresents the true cost burden of
disease, as the annual costs of only seven autoimmune diseases (Crohn's disease,
ulcerative colitis, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis and
scleroderma), have been estimated to total from $51.8-$70.6 billion annually (AARDA,
2011).
Psoriasis. In 2010, the Centers for Disease Control and Prevention (CDC)
initiated a public health agenda for psoriasis in order to better characterize the burden of
psoriasis on the United States population, and to expand the existing knowledge base.
Examining data from the 2003-2006 and 2009-2010 National Health and Nutrition
Examination Surveys, key indicators such as prevalence, severity, disparities, healthrelated quality of life and selected comorbidities were analyzed. The initiative found that
the overall prevalence of psoriasis in the United States is approximately 3.1%, affecting
6.7 million adults aged 20 and greater (Hemlock, Lee-Han, Hirsch, Baird, & Bartlett,
2014). Those with psoriasis tend to have a higher mean age, are more often of nonHispanic white background, suffer from frequent mental distress, depression, arthritis,
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and obesity (Hemlock et al., 2014). The National Foundation of Psoriasis (2008) further
reports that psoriasis is clearly linked with systemic comorbidities, such as cardiovascular
disease and events, hypertension, diabetes, as well as other immune-related diseases.
Psoriasis has also been associated with an increased risk for lymphoma, the strongest risk
was for Hodgkin’s lymphoma, particularly with increased severity of psoriasis (Gelfand
et al., 2006).
A systematic review of the economic burden of psoriasis was published in 2015
(Brezinski, Dhillon & Armstrong). The review concludes that patients with psoriasis
incur annual health care costs that are significantly greater than those of the general
population and may amount to $135 billion annually. In the United States, the economic
burden of psoriasis is substantial because this disease results in considerable negative
physical, psychiatric, and social consequences. The direct psoriasis costs ranged from
$51.7 billion to $63.2 billion, the indirect costs ranged from $23.9 billion to $35.4 billion,
and medical comorbidities were estimated to contribute $36.4 billion annually in 2013.
Patients with psoriasis would pay a lifetime cost of $11,498 for relief of physical
symptoms and emotional health (Brezinski et al., 2015).
Celiac Disease. Celiac disease is one of the recognized immune-mediated
inflammatory diseases, which is caused by a permanent intolerance to the ingestion of
gluten-containing cereals, wheat, rye, and barley, in genetically pre-disposed individuals
(Catassi et al., 2007). Population based studies indicate that the prevalence of CD is
approximately 0.5-1% in Western European and American populations (Tonutti &
Bizzaro, 2014), and the frequency of CD is substantially increased in patients who have a
first-degree family member affected with CD (Rubio-Tapia, Hill, Kelly, & Calderwood,
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2013). In patients with CD, the chronic intestinal damage over time carries risk for
adverse health consequences and increased mortality, including an increased risk for
malignancies such as small-bowel adenocarcinoma, cancer of esophagus, B-cell and Tcell non-Hodgkin lymphomas, and in particular intestinal T-cell lymphomas (RubioTapia et al., 2013). The evidence also suggests that a consequence of untreated CD and
chronic malabsorption of nutrients is an increased prevalence of low bone mineral
density, risk for fractures, and micronutrient deficiencies including iron, folic acid,
vitamins B12 and B6, copper, zinc, and carnitine (Ludvigsson et al., 2014; Rubio-Tapia
et al, 2013). Women with CD have an increased risk of infertility, spontaneous abortions,
preterm deliveries, and delivery of low birth weight infants (Rubio-Tapia et al., 2013). It
is estimated that 83% of Americans who have celiac disease are undiagnosed or
misdiagnosed with other conditions (Fasano et al., 2003). The time from onset of
symptoms to celiac disease diagnosis averages 10 years in the US (Green & Jabri, 2003).
While prevalence is of CD is on the rise, the economic implications of CD are
only just emerging. A 2010 population-based study using administrative data for a cohort
of celiac disease cases and matched controls from Olmsted County, Minnesota were used
to compare direct medical costs one year pre- and post-coeliac disease diagnosis. The
study found that average total costs for patients were reduced by $1,764 in the year
following diagnosis, with a pre-diagnosis cost of $5023 versus a post-diagnosis cost of
$3259 (Long et al., 2010). While additional economic studies are necessary, these results
highlight the importance of early diagnosis and treatment, which may prevent
complications and reduce the economic burden of the disease.
Rheumatoid Arthritis. RA is characterized by inflammation of the synovial
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tissue, which if left untreated, progresses to permanent structural damage and long term
disability (Emery et al., 2002). Epidemiological studies of RA indicate a population
prevalence of 0.5-1.0% in Northern European and North American countries (ElGabalawy, Guenther, & Bernstein, 2010). According to the CDC (2016), an estimated
1.5 million (0.6%) of US adults aged greater than 18 years had RA in the year 2005.
Data from the past decade indicate that the incidence of RA in women appears to be
rising after four decades of decline (CDC, 2016; El-Gabalawy et al., 2010).
Unchecked disease progression in the RA patient increases the incidence of death
due to infection, renal failure, non-Hodgkin’s lymphoma (Emery et al., 2002) (Johns
Hopkins Arthritis Center, 2016) and cardiovascular disease (John’s Hopkins Arthritis
Center, 2016). Cardiovascular disease, including ischemic heart disease and stroke,
accounts for approximately one-third to one-half of RA-related deaths, and infection is
responsible for approximately one-fourth of RA associated deaths (CDC, 2016). Those
with RA who remain untreated are twice as likely to die as compared to those without RA
of the same age (CDC, 2016; Johns Hopkins Arthritis Center, 2016). Additional risks
associated with RA are anemia, osteoporosis and depression (Johns Hopkins Arthritis
Center, 2016) and the possibility of partial or total joint replacement surgeries (Kumar,
Karthik, Gayathri, & Sivasudha, 2016). Approximately 90% of patients with RA have
some form of disability within two decades of onset (Emery et al., 2002).
In 2012, there were 9,100 hospitalizations with RA listed as the principal
diagnosis (Birnbaum et al., 2010). Women and people aged 45 years and older accounted
for the majority of these stays. A study utilizing administrative claims databases
covering privately insured and Medicare and Medicaid beneficiaries in the US during the
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year 2005 were used to estimate the comprehensive cost of RA patients to society and
individual stakeholders (Birnbaum et al., 2010). According to the study, total hospital
charges amounted to $374 million, with a mean charge of $41,000 per person. Direct
out-of-pocket medical costs for patients were estimated to be $8.4 billion, while indirect
costs were estimated to be $10.9 billion, including earning losses, disability payments
and decreased productivity. Finally, the cost of quality of life deterioration and
premature mortality were calculated to be approximately $39.2 billion (Birnbaum et al.,
2010). Early detection and treatment of RA improve the long term patient outcomes and
economic burden of this disease (Emery et al., 2002).
Crohn’s Disease. Crohn’s disease is a chronic, relapsing inflammatory bowel
disease (IBD) that may potentially affect any portion of the gastrointestinal tract from the
mouth to the anus. This condition is characterized by progressive bowel damage
associated with impaired functioning (Peyrin-Biroulet, Loftus, Colombel, & Sandborn,
2010). The highest prevalence for CrD has been found for Europe, 322 per 100,000
people and in North America, 319 per 100,000 people (Laass, Roggenbuck, & Conrad,
2014). According to the Crohn’s & Colitis Foundation of America ([CCFA], 2016),
Crohn’s disease may affect as many as 700,000 Americans. CrD is not gender-biased;
men and women are equally likely to be affected. Further, the disease may appear at any
age, although CrD is more prevalent among adolescents and young adults between the
ages of 15 and 35 (CCFA, 2016).
Patient’s with CrD may suffer from cardiovascular, hepatic, biliary, pancreatic,
and digestive co-morbidities, as well as metabolic issues and psychiatric problems (San
Roman & Munoz, 2011) since symptoms have a substantial impact on quality of life.
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Blockage of the intestine due to swelling and scar tissue is the most common
complication of Crohn’s (CDC, 2014). Patients with CrD are at risk for early small
bowel and colorectal cancer (Baumgart & Sandborn, 2012). Studies also link
extraintestinal inflammatory symptoms with CrD in the eyes, skin or joints (Lichtenstein,
Hanauer, & Sandborn, 2009), as well as ankylosing spondylitis, non-drug induced
osteoporosis, and other inflammatory-mediated immune diseases (Baumgart & Sandborn,
2012). With initiation of corticosteroid therapy, up to 38% of CrD patients will require
surgery within one year (Lichtenstein et al., 2009). Mortality risk has been calculated as
over 50% greater than the general population (Canavan, Abrams, & Mayberry, 2007).
In addition to associated co-morbidities and quality of life issues, the economic
burden on the individual and the United States is substantial. A systematic literature
review of the costs of CrD in Western industrialized countries was conducted for the year
2006 (Yu, Cabanilla, Wu, Mulani, & Chao, 2008). Findings indicated that direct
medical costs per year were $18,022-$18,932 per patient in the United States.
Hospitalizations accounted for 53-66% of these direct medical costs, with a perhospitalization rate of $37,459. The total economic burden of CrD was estimated to be
between $10.9 and 15.5 billion in the United States (Yu et al., 2008).
Summary. By the numbers alone, it is clear that autoimmune disorders, on both
a collective and individual level, should constitute a national, if not global, health crisis
and that additional scrutiny to this category of diseases needs to be made. It is critical
that new methods for facilitating earlier diagnosis of these diseases be developed. Earlier
identification of diseases would lead to the initiation of treatments earlier in the course of
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disease, with the hopes to stave off as much organ destruction as possible, reducing the
long-term consequences, and costs, of the diseases.
1.3 Analysis of Current Practice
General Discussion. Obtaining a diagnosis for a particular autoimmune disease
is typically a long and stressful process for most patients. Many of the initial signs and
symptoms, such as fatigue, joint and muscle pain, fever or weight change (NIH, 2005) are
vague and suggestive of many diagnoses. Practitioners end up treating the symptoms,
without further regard for the etiology of these symptoms, while the disease continues to
progress unchecked. Patients are often required to see multiple practitioners and
specialists before they have been able to get answers and a definitive diagnosis.
According to the AARDA (2011), patients, on average, spent five years seeking a
diagnosis; 46% of patients report being told that they were “constant complainers” or
“too concerned with their health” (p. 9).
Diagnosis of an autoimmune disorder begins with a meticulous health history,
including a careful family history, which might point to a familial tendency toward
autoimmunity. The general concept of shared autoimmunity within families, or the
“kaleidoscope of autoimmunity (Somers, Thomas, Smeeth & Hall, 2009, p. 749)” has
gained acceptance among researchers, and should be a cornerstone of autoimmunity
identification. A careful social history should also be documented, which may help to
identify the patient’s environmental or occupational exposures. Additionally, a complete
physical evaluation has assisted the practitioner in more fully understanding the patient’s
issues (U.S. Department of Health and Human Services, Office on Women’s Health,
2010).
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Laboratory testing remains fundamental to the diagnosis of AI disease in today’s
healthcare setting (Castro & Gourley, 2010). Unfortunately, no one specific test exists to
diagnose autoimmunity. Multiple tests may be run to help support a diagnosis of
autoimmunity, such as the complete blood count (CBC), comprehensive metabolic panel
(CMP), inflammatory markers, autoantibodies, flow cytometry, cytokine analysis, and
HLA typing (Castro & Gourley, 2010). Additionally, non-specific tests, such as the
erythrocyte sedimentation rate (ESR), serum complement markers, ferritin, fibrinogen,
albumin and C-reactive protein (CRP), help to indicate a state of inflammation and allows
the practitioner to evaluate disease activity (Castro & Gourley, 2010). However,
possessing the knowledge about which tests are available for the 80-100+ AI diseases,
and how to interpret them, continues to be a challenge for practitioners today.
In today’s health care arena, AI diseases are managed as individual entities, via
disease-specific profiles, as opposed to a general immune-related profile (Rahman et al.,
2010). Guidelines have been developed to help practitioners with the diagnosis and
treatment of psoriasis, CD, RA and CrD. The standards of care and current diagnostic
approaches for these four IMIDs will be discussed below.
Psoriasis. Psoriasis commonly presents in the primary care setting (Krueger &
Bowcock, 2005) and is a chronic, inflammatory, papulo-squamous skin disease.
Hyperplasia of skin epithelial cells lead to well-circumscribed, raised, red lesions, with
loosely adherent silvery white scales. Common locations are the knees, elbows and
scalp. Approximately 10-30% of patients also develop psoriatic arthritis (PsA), a painful
joint condition (Aldredge, 2015).
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While a plethora of guidelines exist to direct the management and treatment of
psoriasis, no published diagnostic criteria have been developed. Diagnosis is dependent
primarily on the practitioner’s recognition of characteristic skin and lesion patterns, using
a subjective, qualitative assessment of the patient’s skin (Menter et al., 2008;
Raychaudhuri, Maverakis, & Raychaudhuri, 2014). A timely and proper diagnosis,
therefore, is based wholly upon the practitioner’s general knowledge of psoriatic
morphology and phenotype.
Johnson and Armstrong (2012) published a set of clinical and histologic
diagnostic guidelines for psoriasis, specifically for non-dermatologist practitioners. The
authors acknowledge that while no established criteria exist for skin-limited psoriasis,
trained health care providers should be able to diagnose psoriasis based on clinical
history and skin examination. The guidelines (Johnson & Armstrong, 2012) do not offer
absolute criteria for diagnosing psoriasis, however, they provide a set of
recommendations that providers should take into consideration during the assessment and
diagnosis of psoriasis.
Among these recommendations is to obtain a complete clinical, family and social
history (Armstrong & Johnson, 2012). Clinical history should include onset of lesions,
triggering factors, and associated symptoms (itch, pain, sensitivity, irritation). Family
history should be discussed due to genetics and heritability of this IMID. Social factors
should also be discussed, due to the association of psoriatic exacerbations with stress,
smoking and alcohol. Finally, the provider must conduct a full skin examination to
include the nails, scalp and intertriginous areas. Health care providers should take special
notice of the characteristic morphology of the erythema, scaling and induration of lesions
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(Armstrong & Johnson, 2012). Although not included in the Armstrong and Johnson
guidelines, psoriasis classification can include the following morphologies, which may
present differently in patients and often, present with overlapping clinical findings:
plaque, inverse, erythrodermic, pustular, guttate, nail disease and psoriatic arthritis
(Menter et al., 2008).
Histopathology and skin biopsy, while an option for the diagnosis of psoriasis, is
not routinely practiced or required. However, if a question remains on the diagnosis,
histopathology can be beneficial in distinguishing psoriasis from other inflammatory skin
diseases (Armstrong & Johnson, 2012).
Celiac Disease.

Celiac disease is a chronic, immune-mediated inflammatory

disease that manifests with a range of clinical symptoms in individuals who are
genetically susceptible. The consumption of gluten-containing foods triggers an immune
reaction, and a subsequent, inflammatory state of the duodenal mucosa (Tonutti &
Bizzaro, 2014). The immune response is directed against both the exogenous gluten
antigen and the autoantigen, tissue transglutaminase (tTG), which is a gluten byproduct
created in the small intestine (Kagnoff, 2006).
Clinical manifestations of CD can vary widely, and there is no concrete consensus
regarding which symptoms, laboratory abnormalities or associated diseases require
further evaluation for CD. Generally speaking, diagnosis begins with a health care
provider’s strong suspicion of CD based on the clinical exam and initial laboratory
results.
According to the guidelines developed by the American College of
Gastroenterology, individuals with signs, symptoms or laboratory evidence suggestive of
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malabsorption, such as chronic diarrhea, weight loss, iron deficiency anemia (IDA) or
elevated liver enzymes, and/or steatorrhea, postprandial abdominal pain, and bloating,
should be tested for CD (Rubio-Tapia et al., 2013). Guidelines from the British Society
of Gastroenterology (Ludvigsson et al., 2014) state that CD can be suspected in patients
with mild gastrointestinal symptoms, associated conditions, or those at genetic risk, to
include symptomatic first-degree relatives of patients with CD, as well as symptomatic
individuals with Down’s Syndrome and Turner’s Syndrome (Ludvigsson et al., 2014).
However, since the clinical picture of CD varies, and since many patients only have
minor symptoms, it can be challenging for health care providers to make that first
connection, from symptoms to suspicion.
Further confusing the diagnostic process is the fact that CD has been classified
into multiple phenotypes: classic, atypical, silent, latent and refractory (Kagnoff, 2006).
“Classic” CD is the most commonly described form, and patients present due to
gastrointestinal symptoms. Whereas “classic” CD is the most commonly described form,
“atypical” CD is actually the most prevalent form. Patients have little to no GI issues, but
they become identified for other reasons, such as IDA, osteoporosis or infertility.
“Silent” CD describes the cohort of patients who are asymptomatic, but who diagnose
positive for CD as a result of serology or biopsy done for another reason. “Latent” CD
refers to patients who previously have been diagnosed with CD, who responded to a
gluten-free diet (GFD) and who retain normal mucosal histology. “Refractory” CD
represents patients with true CD, who no longer respond to a GFD. (Kagnoff, 2006;
Tutonni & Bizarro, 2014).
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Regardless of how a patient comes to the attention of the practitioner as
potentially having CD, the next steps in diagnosis are well agreed upon. The first step in
diagnosis is serology, followed by a biopsy, which is considered to be the gold standard
for CD diagnosis (Green & Jabri, 2003; Kagnoff, 2006; Ludvigsson et al., 2014; RubioTapia et al., 2013; Tonutti & Bizzaro, 2014). The Immunoglobulin A (IgA) anti-tissue
transglutaminase (tTG) antibody is the preferred serological test for individuals over the
age of 2 years. Both the sensitivity and specificity of the IgA-tTG for untreated CD is
approximately 95% (Kagnoff, 2006; Rubio-Tapia et al., 2013). If IgA deficiency is a
concern, occurring in 1.7%-2.6% of patients with celiac disease (Green & Jabri, 2003),
total serum IgA should be included in the panel and both IgA and IgG-based testing may
be initiated to include the IgG-deamidated gliadin peptides (DGPs) (Green & Jabri, 2003;
Rubio-Tapia et al., 2013). With known IgA deficiency, both IgG-DGPs and IgG-tTG
serology may be tested. Finally, if serology is negative, but suspicion for CD is high,
intestinal biopsy should be pursued (Green & Jabri, 2003; Kagnoff, 2006; Ludvigsson et
al., 2014; Rubio-Tapia et al., 2013; Tonutti & Bizzaro, 2014).
The intestinal biopsy remains the gold standard in diagnosis because results
reflect the varying degrees by which mucosal villi have been affected over the course of
the disease. The Marsh-Oberhuber classification of architectural changes in the intestine
outline three categories of lesion: “Type 1” describes an infiltrative lesion, “type 2” an
infiltrative-hyperplastic lesion, and “type 3” reports mild, moderate and total levels of
villous atrophy (Tonutti & Bizzaro, 2014). Multiple samples should be taken from the
second or third portion of the duodenum and at least one sample from the duodenal bulb
(Tonutti & Bizzaro, 2014).
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In the setting where results from the aforementioned tests are not clear, or for
patients already on a GFD, individuals can be genotyped for the gene pairs that encode
HLA class II heterodimer HLA-DQ2 or HLA-DQ8. Almost all patients with CD have
either DQ2 (~95% of CD patients) or DQ8 (the remaining ~5% of CD pts) and the
absence of both of these DQ alleles provide a negative predictive value for the disease of
close to 100% (Kagnoff, 2006; Green, 2003; Ludvigsson et al., 2014).
Rheumatoid Arthritis. The three major pathways for this immune-mediated
inflammatory disease include bone degradation, cartilage and synovial destruction, which
lead to severe disability and premature mortality (Aletaha et al., 2010). While the precise
etiology and pathophysiology of RA is not completely understood, at least 16 different
cytokines, autoantibodies and other mediators are implicated in the disease process
(Kumar et al., 2016). The initial immune response, the pre-articular phase, begins with
the generation of autoantibodies against own tissue components. During the transition
phase, the introduction of autoantibodies and autoantigens in the articular joints becomes
evident, causing joint destruction to occur symmetrically to joints all over the body,
although the distal interphalangeal and cervical spine is typically spared (Kumar et al.,
2016). Permanent structural damage occurs early in the disease course of RA and early
intervention with disease modifying anti-rheumatics drugs (DMARDs) treatment is
critical toward slowing the progression of joint damage, improving quality of life and
long term outcomes for patients (Emery et al., 2002).
The American College of Rheumatology (ACR) and the European League
Against Rheumatism (EULAR) collaborated to update the classification criteria for RA
that was last published in 1987 (Cohen & Emery, 2010). The criteria were developed to
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help researchers classify newly presenting patients and to help determine which patients
would benefit from early treatment (Aletaha et al., 2010). The expert panel identified the
following mandatory criteria: pattern and extent of joint involvement, serology
(rheumatoid factor (RF) and anti-cyclic citrullinated protein (ACPA)), acute-phase
response (C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) and
duration of symptoms (Aletaha et al., 2010; Neogi et al., 2010). Two criteria were
deemed essential. First, the patient must present clinically with joint swelling in at least
one joint, indicating synovitis, and second, there must also be an absence of another
condition that could explain the patient’s symptoms. Differential diagnoses include
multiple disorders such as psoriatic arthritis, systemic lupus erythematous (SLE),
osteoarthritis and gout. The authors of the classification criteria suggest that if it is
unclear to the provider which relevant differential diagnoses to consider, a rheumatologist
should be consulted (Aleteha et al., 2010).
The remaining four criteria each contribute differently to the probability of
developing RA and were weighted accordingly during the criteria development (Aleteha
et al., 2010). The table below shows the criteria and scoring, with a required score of 6 or
greater to be classified as having definite RA.
Table 1.1 The 2010 American College of Rheumatology/European League Against
Rheumatism Classification Criteria for Rheumatoid Arthritis
The 2010 American College of Rheumatology/European League Against Rheumatism
classification criteria for rheumatoid arthritis
Target population (who should be tested?) Patients who:
1) Have at least 1 joint with definite clinical synovitis (swelling),
2) With the synovitis not better explained by another disease.
Classification criteria for RA (score-based algorithm): add score of categories A-D:
a. A score of ≥ 6/10 is needed for classification of a patient as having definite RA.
A. Joint Involvement
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1 large joint
0
2-10 large joints
1
1-3 small joints (with or without large joint involvment 2
4-10 small joints
3
> 10 joints (at least 1 small joint)
5
B. Serology
Negative RF and negative ACPA
0
Low-positive RF or low-positive ACPA
2
High-positive RF or high-positive ACPA
3
C. Acute-phase reactants (at least 1 test result required for classification)
Normal CRP and normal ESR
0
Abnormal CRP or abnormal ESR
1
D. Duration of symptoms
< 6 weeks
0
≥ 6 weeks
1
(Reproduced from Aletaha et al., 2010)
Although not included in the new classification criteria, radiograph imaging is
used to assess the structural damage associated with RA, and continues to be the best
method for collecting data on joint erosions and bone density. Other markers
traditionally used by providers to diagnose RA, such as the assessment of morning
stiffness and the metacarpal “squeeze test” (Emery et al., 2002), have also been excluded
from the classification criteria.
One point must be elucidated about the classification criteria. These criteria were
deliberately labeled “classification,” as opposed to “diagnostic” criteria, in order to
provide a standardized approach for determining which patients presenting with
undifferentiated synovitis, would have the highest probability of persistent or erosive RA
(Aletaha et al., 2010). As such, the authors acknowledge that the criteria may in fact be
used as a tool for diagnosis, but that easier-to-use tools are in development through
another joint effort by ACR/EULAR for primary care providers.
Crohn’s Disease. Crohn’s disease is a chronic, progressive, destructive
inflammatory bowel disease (IBD) of the GI tract, manifesting anywhere from the mouth
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to the anus. Ulcerative colitis (UC) is the second disease included in the IBD
classification. By comparison to CrD, which is intermittent inflammation and can attack
all bowel wall layers, UC is a continuous inflammation that it is limited to only the
innermost layer of the intestinal linings in the colon and rectum (CCFA, 2016). Both
IBDs are characterized by periods of disease activity interspersed with periods of
remission. Symptoms of both CrD and UC may include fever, bloating, cramping,
nausea, vomiting, severe diarrhea, bloody stool, abdominal pain, weight loss and fatigue.
CrD patients may also have mucous in their stool (Laass et al., 2014). Patients can have
symptoms for many years prior to diagnosis (Burgmann et al., 2006; Pimentel et al.,
2000).
The rationale for defining early Crohn’s disease is to modify the clinical course of
the disease and intervene prior to the onset of bowel damage in the form of stricture,
fistula, or abscess. However, approximately one-fifth of adult patients already have
evidence of structuring or penetrating intestinal complications at diagnosis (PeyrinBiroulet et al., 2010). CrD is a seronegative IMID, meaning there is no direct serological
test for detecting disease activity. And presently, there is no gold standard for CrD
diagnosis. Diagnosis integrates patient information and physical exam with objective
data from a combination of laboratory, radiologic, endoscopic and histologic findings
(Laass et al., 2014; Peyrin-Biroulet et al., 2010; Van Assche et al., 2009; (Baumgart &
Sandborn, 2012). Genetic testing is not currently recommended (Lichentstein, 2009;
Peyrin-Biroulet, 2010; Van Assche et al., 2009).
The most common presenting CrD symptom is chronic diarrhea, defined as a
decrease in fecal consistency for more than 4 to 6 weeks (Laass et al., 2014). Abdominal
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pain is seen in about 70% of patients before diagnosis, and approximately 60% of
patients experience weight loss (Van Assche et al., 2009). In approximately 10% of
patients, the presenting complaint is a perianal fistula (Van Assche et al., 2009).
Providers must take a complete medical history itemizing symptoms and inquire about
family history, as first-degree relatives of patients with IBD have a 10-15 fold risk for
also having IBD (Laass et al., 2014). A full history should also include information about
recent travel, food intolerances and medications. Attention should be paid to proven risk
factors including smoking and recent infectious gastroenteritis (Van Assche et al., 2009).
Physical examination includes general well-being, vital signs, body weight, BMI,
abdominal tenderness or distention, palpable masses, perineal and oral inspection, rectal
digital examination (Van Assche et al., 2009; Laass et al., 2014) plus signs of
extraintestinal disease. Extraintestinal manifestations might present as joint pain,
swelling, redness or stiffness, erythema nodosu, or redness of the eye (Laass et al., 2014).
Clinical laboratory testing continues the inflammatory status assessment, although
of and by themselves, labs are not enough to differentiate CrD from UC or enteric
infection. The initial lab investigations support GI inflammation and are used as an
adjunct to diagnosis (Van Assche et al., 2009). Patients should be assessed for anemia,
fluid depletion and signs of malnutrition or malabsorption via the complete blood count
(CBC). Anemia and thrombocytopenia represent the most common changes in CBC
evaluation of patients with CrD (Van Assche et al., 2009). CRP and ESR are nonspecific acute phase inflammatory markers that should be evaluated. Fecal calprotectin
or lactoferrin provides an estimation of fecal inflammation by measuring for the presence
of fecal leukocytes (Lichtenstein et al., 2009). Fecal calprotectin has a positive predictive
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value of 85-90% in distinguishing IBD from irritable bowel syndrome (IBS). Stool
cultures are beneficial for ruling out infectious colitis caused by viral, bacterial or
parasitic sources (Laass et al., 2014; Van Assche et al., 2009; Lichentenstein et al., 2009).
Providers must also consider lactose intolerance and celiac disease in their list of
differential diagnoses.
Upper or lower GI endoscopy is used to confirm the diagnosis of CrD, assess
disease location, and obtain tissue for pathological examination (Laass et al., 2014; Van
Assche et al., 2009). However, the initial symptoms frequently determine the order of
subsequent testing. For example, colonoscopy, intubation of the terminal ileum, is the
most appropriate initial test for patients presenting with predominant diarrhea, and is used
to establish the diagnosis of ileocolonic CrD. On the other hand, imaging studies may be
more appropriate for those presenting with abdominal pain. Magnetic resonance
enterography is the initial test used to evaluate the small intestine. Wireless video
endoscopy, or video capsule endoscopy (VCE), may also be useful for detecting small
bowel involvement (Laass et al., 2014; Van Assche et al., 2009).
1.4 Statement of Problem/Purpose
In adult patients aged 18 years and greater with psoriasis, does screening for
celiac disease, rheumatoid arthritis, and crohn’s disease improve early detection for these
autoimmune disorders? The Population (P) in this question is adult patients aged 18
years and greater in primary care and outpatient settings. The Intervention (I) is the
development and implementation of a simple screening tool in adults patients with
psoriasis for celiac disease, rheumatoid arthritis and crohn’s disease. There is no
Comparison (C) for this background-type question. The Outcome (O) is demonstrating
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improved early detection of celiac disease, rheumatoid arthritis and crohn’s disease in
adult patients with psoriasis. Table 1.1 contains the definitions of population, setting,
intervention, and outcome as defined by Melynk & Fineout-Overholt (2011). The
purpose of this project is to conduct a substantive review of the literature to determine if
screening primary care patients with psoriasis will improve early detection of celiac
disease, rheumatoid arthritis, and Crohn’s disease.
Table 1.2 PICO Definitions
Population of
Interest
In adult
patients over
ages 18 with
psoriasis

Setting

Current Practice

Primary
No screening
care or
outpatient
settings

Intervention

Outcome

Screening
for celiac
disease,
rheumatoid
arthritis and
Crohn’s
disease

Improved early
detection of celiac
disease, rheumatoid
arthritis and Crohn’s
disease as measured by:
a provider
documentation for
screening those with
psoriasis for celiac
disease, rheumatoid
arthritis and Crohn’s
disease.

1.5 Project Questions
The project was guided by the following clinical questions:
What is autoimmunity? What is polyautoimmunity? What are IMIDs?
Why is it so difficult for patients with autoimmune diseases to become diagnosed?
Is there evidence that suggests that individuals with one autoimmune disease are
more at risk for developing another autoimmune disease?
Is there evidence that suggests that individuals with psoriasis have a greater risk
of developing celiac disease, rheumatoid arthritis or Crohn’s disease?
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What are the current, accepted approaches for diagnosing psoriasis, celiac disease,
rheumatoid arthritis and Crohn’s disease?
Would screening patients with psoriasis for celiac disease, rheumatoid arthritis
and Crohn’s disease improve early detection for these diseases?
1.6 Definitions
Adult Patients – Adult patients refer to men and women over the age of 18 years
seeking health care in a primary care setting.
Celiac Disease - Celiac disease is an autoimmune disease that causes an
inflammatory reaction to ingested gluten, a protein found in wheat, rye, and barley.
When a person has celiac disease, gluten causes the immune system to react in a way that
can cause intestinal inflammation—irritation or swelling—and long-lasting damage
(NIH, 2015).
Crohn’s Disease - Crohn’s disease is an autoimmune disease characterized by
chronic, relapsing inflammation to any portion of the gastrointestinal tract from the
mouth to the anus. Also known as one of the inflammatory bowel diseases (IBD), this
condition is caused by an abnormal response to the body's immune system which results
in progressive bowel damage associated with impaired functioning (Peyrin-Biroulet et al.,
2010; CDC, 2014).
Early Detection - Early detection refers to a screening program that detects
disease in asymptomatic persons or in symptomatic persons not yet recognized to have
disease. Relative to background conditions, screening identifies the affected individual at
an earlier time point in the natural history of disease (Weissfeld, 2001).
Health Screening - Health screenings include specific technology (survey
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questionnaire, physical observation or measurement, laboratory test, radiological
procedure, etc.) that are used to help identify persons with unrecognized disease or
unrecognized risk factors for disease (Weissfeld, 2001).
Rheumatoid Arthritis – Rheumatoid arthritis is an autoimmune disease
characterized by chronic, systemic inflammation of the synovial tissue. If left untreated,
RA progresses to permanent structural damage and long-term disability (CDC, 2016;
Emery et al., 2002).
Primary Care Providers - A primary care provider (PCP) is a health care
practitioner who is responsible for monitoring an individual's overall health care needs.
The PCP's role is to provide preventative care and teach healthy lifestyle choices, identify
and treat common medical conditions, assess the urgency of medical problems and direct
the patient to the best place for their care, and make referrals to medical specialists when
necessary (She, 2012).
1.7 Chapter Summary
Research suggests (Cooper, Bynum & Somers, 2009) that individuals with one
autoimmune disease typically will develop an additional one or more separate, and
distinct, autoimmune diseases over the course of their lifetime. Further, links have been
drawn between psoriasis and celiac disease, rheumatoid arthritis and crohn’s disease
(Augustin, Reich, Glaeske, Schaeffer & Radtke, 2010; Ali & Warren, 2013; Wu, Nugyen,
Poon & Herrington, 2012; Guerin, Zhang, Gauthier, Day & Khan, 2012; Hsu &
Armstrong, 2012; Makredes, Robinson, Bala & Kimball, 2009; Birkenfeld, Dreiher,
Weitzman & Cohen, 2009; Tsai, Wang, Hung, Tsai, Schenkel, Zhang & Tang, 2011).
Regrettably, practitioners may overlook the associations between these autoimmune
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diseases, prolonging the diagnostic process (Somers et al., 2009). The purpose of this
project is to conduct a substantive review of the literature to determine if screening
primary care patients with psoriasis will improve early detection of celiac disease,
rheumatoid arthritis, and Crohn’s disease. The aim of this project is to assess the utility
of early screening in patients with psoriasis in order to facilitate earlier diagnosis of CD,
RA and CrD, which would consequently initiate earlier treatment and improve long-term
patient outcomes.
The next step in the evidenced-based practice process is the literature search and
analysis. The evidence will be organized using an evidence table. This process is
explained in detail in chapter II.
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Chapter 2
Literature Review
2.1 Introduction
The goal of this chapter is to appraise and synthesize the evidence for conducting
the DNP project for changes in practice. The discussion that follows describes the
literature search process, and an objective summary and analysis of fourteen research
articles. The purpose of this content is to convey the current state of knowledge, and
significance of, the relationship between psoriasis and the three IMIDs of interest (celiac
disease, rheumatoid arthritis, and Crohn’s disease) to healthcare providers and decision
makers.
2.2 Search Methodology
Evidence-based practice mandates that clinical decisions be driven by the most
current research studies, the clinical experience of the practitioner, and patient
preferences (Melnyk & Fineout-Overholt, 2011). Evidence-based research begins with a
question of interest, followed by the systematic collection, appraisal and synthesis of
evidence. The following information presents the search strategy employed for the
question: in adult patients aged 18 years and greater with psoriasis, does screening for
celiac disease, rheumatoid arthritis, and Crohn’s disease improve early detection for these
autoimmune disorders?
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This is a background-type PICO question and according to Melnyk and FineoutOverholt (2011), the following types of studies are appropriate for review, in descending
order of level of evidence: synthesis of cohort study or case control studies, single cohort
studies or case-control studies, meta synthesis of qualitative or descriptive studies, single
qualitative or descriptive studies, and expert opinion. A search of databases was
performed, accessed through the University of South Carolina’s online library. The
Cumulative Index for Nursing and Allied Health Literature (CINAHL), PubMedMedline, Medline OVID, Cochrane Library, Web of Science, Essential Evidence Plus,
Nursing Resource Center, Health Source: Nursing/Academic Edition, Dissertations and
Thesis, Annual Reviews, as well as Google Scholar were included in the search.
Reference lists of acceptable papers were also manually examined for additional
resources.
The main search terms were “psoriasis” and “autoimmunity.” Limitations were
set for the years 2006-2016, in order to review the most up-to-date research and evidence
on the topic, and for English-only papers, to eliminate language barriers. Additional
cross-searching terms utilized were “co-autoimmunity,” “co-existence,” “association,”
“pan autoimmunity,” “immune mediated inflammatory diseases,” or “IMIDs,” and
“screening.” Finally, “psoriasis” was searched specifically against the three AI disorders
of interest for this project: “celiac disease,” “Crohns disease,” and “rheumatoid arthritis.”
A total of fourteen papers were selected. Levels of evidence were appraised
using the Scottish Intercollegiate Guidelines Network (SIGN) rating system (Appendix
A). The rating scale ranges from 1++, the highest level of evidence, reserved for high
quality meta-analysis, systematic reviews of RCTs, or RCTs with a very low risk of bias,
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to 4, reserved for expert opinion, the lowest level of evidence. Four retrospective cohort
studies with control groups were found (level of evidence 2+). Four case-control studies
(level of evidence 2+), one cross-sectional study (level of evidence 3), two meta-analysis
of genetic studies (level of evidence 1+), one meta-analysis of population based studies
(level of evidence 1+), one prospective cohort study (level of evidence 2+), and one
expert review paper (level of evidence 4) were included.
2.3 Analysis of the Evidence
Evidence was organized in table format with the following headings: brief
reference, type of study/quality ratings, methods, threats to validity/reliability, findings
and conclusions (Appendix B). The table was developed to consolidate methodological
and outcome summaries from the selected articles and used for the purpose of synthesis
and analysis. Each evidence-based, peer reviewed article was systematically appraised
on the individual level, followed by an overall summary of findings. The four genetic
studies are presented first, followed by the population-based studies. For the purposes of
this literature review, when studies include multiple AI disorders, only the four AI
diseases directly related to this study, psoriasis, celiac disease, rheumatoid arthritis, and
Crohn’s disease, will be discussed.
2.4 Genetic Studies.
Four of the fourteen research articles included in this review can be classified as
genetic studies. What follows is a brief discussion to foster a basic understanding of
single nucleotide polymorphisms (SNPs), the main concept in each of the studies.
From a top down perspective, all cells in the body contain a nucleus, which then
contains 23 pairs of chromosomes. Each tightly packed chromosome unravels to reveal a
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double helix of deoxyribonucleic acids, or DNA. The DNA double helix is composed of
a long sequence of nucleotide base pairings, adenine (A), thymine (T), guanine (G) and
cytosine (C). These nucleotide bases link in a very specific way: A always pairs with T,
and C always pairs with G. Distinct sequences of these nucleotides organize the
chromosomes into sub-units, which are genes. Genes provide the cell with the
instructions that dictate cell function (National Human Genome Research Institute, 2015).
A SNP is defined as a single nucleotide base change in a DNA sequence that
occurs in a significant proportion (more than 1 percent) of a large population (University
of Utah Health Sciences, 2016). To make an analogy, 99% of the population has a
sequence for “Marie,” while approximately 1% has a sequence for “Maria.” Today’s
challenge for researchers is to identify SNPs, or the “Maria’s,” that correlate with a
particular effect in patients. Genetic association studies, such as the ones to follow,
compare the frequency of genotypes at genetic marker loci, usually single-nucleotide
polymorphisms (SNPs), in individuals with and without a given disease trait from a given
population. The objective of these association studies is to determine whether a
significant statistical association exists between the disease trait and the genetic marker
(Clarke, Anderson, Peterson, Cardon, Morris & Zondervan, 2011). Reliable SNPs could
serve as predictive gene markers that inform decisions about numerous aspects of
medical care, including specific disease diagnosis, predisposition to disease, and the
effectiveness of various drugs and adverse reactions to specific drugs (University of Utah
Health Sciences, 2016).
Association of SNP Gly307Ser (rs763661) with Psoriasis, CD & RA. Qiu,
Khang, X. Qiu, Zhou and Li (2013) conducted a meta-analysis to evaluate the
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relationship between the non-synonymous single nucleotide polymorphism (SNP)
Gly307Ser (rs763361) in the CD226 gene that has been reported to be associated with
several AI diseases, including psoriasis, celiac disease, and rheumatoid arthritis. Whether
the presence of this t allele rs763361 confers a risk for multiple AI diseases remains
under investigation. This study was rated a 1+.
The authors conducted a comprehensive search of the U.S. National Library of
Medicine’s PubMed and Embase databases for studies that fulfilled the following
inclusion criteria: (1) were based on case-control design, (2) evaluated the association of
the Gly307Ser (rs763361) polymorphism with multiple autoimmune disorders, (3)
disease diagnosis followed the diagnosis criteria of the World Health Organization
(WHO), (4) genotype frequencies were provided, (5) authors provided sufficient data for
estimating an odds ratio and their 95% confidence interval (CI), and (6) papers were
published with full text articles (Qui, Z., Zhang, X. Qui, Zhou & Li, 2013). Seven
published studies met the inclusion criteria, covering 7,876 cases and 8,558 controls. The
sample sizes varied from 90 to 2,838 and included two European, two Asian, one South
American and three Estonian studies. The studies utilized three different genotyping
methods, polymerase chain reaction-restriction fragment length polymorphism (PCRRFLP), TaqMan genotyping and SNPlexTM (Qui, et al., 2013).
Qui et al. (2013) used STATA 12.0 software for statistical analysis and estimated
the association between CD226 Gly307Ser (rs763361) polymorphism and multiple AI
diseases using crude odds ratio (OR) with 95% CIs. As is appropriate for meta-analyses,
the authors assessed the degree of inconsistency in the studies' results, or between-studies
heterogeneity, using Q-test and I2 statistics. The DerSimonian and Laird random-effect
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model calculated pooled estimates in case of significant heterogeneity. In cases without
obvious heterogeneity, the Mantel-Haenszel fixed-effect model estimated a summary OR.
The evaluation of the association of CD226 Gly307Ser (rs763361) polymorphism
with multiple AI diseases demonstrated an overall OR 1.19 (95% CI: 1.12-1.27,
Pheterogeneity=0.136), indicating that a significantly increased multiple AI disease risk was
found to be associated with the t allele rs763361 (Qui et al., 2013). The authors also
conducted a subgroup analysis by ethnicity, where increased risks were found for South
Americans (OR=1.31, 95% CI=1.17-1.48, Pheterogeneity = 0.644), Asians (OR=1.23, 95%
CI=1.11-1.38, Pheterogeneity = 0.690), and Europeans (OR=1.13, 95% CI=1.04-1.24,
Pheterogeneity = 0.085) (Qui et al, 2013).
Although heterogeneity was detected in both the overall comparison and in the
subgroup analyses, none were notable (Pheterogeneity = 0.136, I2=29.3% in overall
comparsion; Pheterogeneity = 0.644, I2=0.0% in South Americans; Pheterogeneity = 0.690,
I2=0.0%; Pheterogeneity = 0.085, I2=46% in Europeans). Meta-regression analysis was
performed to explore sources of heterogeneity across studies when statistical
heterogeneity was detected. Publication year was closely related to the heterogeneity in
allele comparison (I2=11.9%, P=0.036), while racial descent, study sample size,
genotyping methods, and controls’ source did not indicate any modifying effect of the
factor (P>0.05) (Qui et al, 2013).
Further, Begg’s test suggested no significant publication bias and the HardyWeinberg equilibrium was demonstrated by using the Fisher’s exact test (p < 0.10).
Finally, the authors conducted a sensitivity analysis to assess the stability of results. The
sensitivity analysis indicated that no individual study significantly affected the pooled
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OR, and that results were statistically robust. The authors, however, acknowledged
limitations to this study. First, this study lacked the original information for the
individuals in the included studies; as such, data could not be stratified by other variables,
such as gender, and mean age at onset (Qui et al, 2013). The lack of original data also
means that the authors would not have been able to validate each case for the metaanalysis. Therefore, the possibility of diagnoses misclassification in the original studies
cannot be completely excluded. Second, races other than South American, Asian,
European and Estonian were not represented in this meta-analysis. Third, the authors
note that while their publication bias showed no significance, it cannot be completely
ruled out due to exclusion of relevant publications that were not indexed by their selected
databases, PubMed and Embase (Qui et al, 2013).
The results of this meta-analysis, that a significantly increased multiple AI disease
risk was found to be associated with the t allele rs763361, highlight the evolving
comprehension of co-autoimmunity. It further supports the concept that susceptibility to
AI diseases may be due to a complex interaction of multiple genes, some of which seem
to be shared among many of these AI diseases, including psoriasis, celiac disease and
rheumatoid arthritis.
15 New Psoriasis Susceptibility Loci. Tsoi et al. (2013) conducted a metaanalysis of three GWAs and two independent datasets genotyped on the “Immunochip,”
to include a total of 10,588 cases (patients with psoriasis) and 22,806 controls. The
“Immunochip” is a custom-designed SNP array whose function is to fine-map genomewide significant (P<5x10-8) susceptibility loci and to explore replication of thousands of
SNPs representing additional promising signals. Tsoi et al. and other investigators of 12
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distinct autoimmune and inflammatory diseases designed the chip in 2009 (Parkes,
Cortes, Van Heel & Brown, 2013).
The Immunochip consists of 196,524 SNPs compiled from variants identified in
previous GWAS of 12 different IMIDs. Each disease-focused group involved in the chip
design were then allowed to submit approximately 3000 additional SNPs in order to
evaluate signals that were deemed promising or that had not quite met genome-wide
significance in previous studies (Tsoi et al, 2013). The main objective of this study was
to increase understanding of the genetic architecture of psoriasis, identify new genetic
determinants of psoriasis, and to relate them to other AI diseases (Tsoi et al., 2013). This
study has been rated a 1+.
The authors performed a meta-analysis from five datasets that were genotyped on
the Immunochip. These datasets included three existing GWAS (Kiel, CASP and
WTCCC2) and two independent European descent case-control datasets, the Psoriasis
Association Genetics Extension (PAGE) and the Genetic Analysis of Psoriasis
Consortium (GAPC) (Tsoi et al., 2013). Prior to meta-analysis, a number of quality
control steps were taken by the authors in order to identify and remove DNA samples and
markers that could introduce bias into the study. SNPs with a call rate below 95% were
excluded. Using the HapMap 3 samples as a reference, the authors performed principal
component (PC) analysis to identify and remove samples with non-European ancestry.
Samples with extreme inbreeding coefficients or heterozygosity values were also
removed, as were duplicate pairs or highly related individuals. A principle component
(PC) analysis was also used on each individual dataset to assess for possible population
stratification; no evidence of stratification between cases and controls within each dataset
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was found. Finally, imputation was performed on the datasets in order to increase the
number of overlapping SNPs between datasets. SNPs with low imputation quality were
removed (Tsoi et al., 2013).
The meta-analysis revealed genome-wide significance (P<5x10-8) for 19 of the 21
known psoriasis loci. The analysis demonstrated nominal evidence for the two remaining
loci. Fifteen new risk loci for psoriasis were also identified that fulfilled genome-wide
significance (Tsoi et al., 2013). Of the total 39 known and new psoriasis susceptibility
loci included in this study, ten of these loci overlapped with Crohn’s disease, nine with
celiac disease, and five with rheumatoid arthritis. A table has been provided below to
provide a snapshot view of SNPs (known versus new) relative to disease overlap. The
table also includes each SNP combined p-value and meta OR from analysis, as well as
the notable genes associated with each SNP.
Table 2.1 SNP Disease Overlap

Known Loci
SNP
rs9988642

Combined P-value
1.1×10-26

OR (meta)
1.52

Notable genes
IL23R

Disease overlap
CrD

rs62149416

1.8×10-17

1.17

FLJ16341, REL

RA, CrD, CD

rs27432

1.9×10-20

1.20

ERAP1

CrD

rs1295685

3.4×10-10

1.18

IL13, IL4

CrD

rs2233278

2.2×10-42

1.59

TNIP1

CrD

rs12188300
rs582757
rs1250546
rs34536443

3.2×10-53
2.2×10-25
6.8x10-7
9.1×10-31

1.58
1.23
1.10
1.88

IL12B
TNFAIP3
ZMIZ1
TYK2

CrD
CD, RA
CD, CrD
CrD

rs4821124

3.8×10-8

1.13

UBE2L3

CD, RA, CrD
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Newly Identified Loci
SNP
rs11121129

Combined P-value
1.7×10-8

OR (meta)
1.13

Notable genes
SLC45A1,
TNFRSF9

Disease overlap
CD

rs7536201

2.3×10-12

1.13

RUNX3

CD

rs9504361

2.1×10-11

1.12

EXOC2, IRF4

CD

rs2451258

3.4×10-8

1.12

TAGAP

CD, CrD, RA

rs2700987

4.3×10-9

1.11

ELMO1

CD, RA

(Tsoi et al., 2013)
It is important to emphasize that the authors suitably denote a very low threshold
P-value supportive of genome-wide significance, indicating that the association is not due
to chance alone. In a meta-analysis study where a large number of variants are being
studied, the low P-value is required in order to protect against the production of large
numbers of false positives (Type I error); however, such a conservative approach may
therefore cause variants with small real effects to be overlooked, leading to false
negatives (Type II error) (Thompson, Attia & Minelli, 2011). To overcome Type II error,
sample sizes must be large enough to achieve sufficient power to identify such SNPs.
Using large combined datasets significantly increases the power in GWA studies
(Thompson, Attia & Minelli, 2011).
A notable limitation with GWAS studies is that they are only able to detect an
association for a genomic region, and not causation of a mutation, that may be involved
in the development of the disease or trait. Additionally, SNPs typically only explain a
small fraction of an individual’s risk for the trait (Genetics and Social Science, 2016).
Tsoi et al. (2013) report that the 41 independent signals with P<5x10-8 collectively only
account for 14.3% of the total variance in psoriasis risk, or approximately 22% of its
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estimated heritability. One explanation for the missing heritability is that complex
diseases are caused by a large number of causal variants with small effect sizes (Stringer,
Wray, Kahn and Derks, 2011). The small effect sizes are reflected in the odds ratios
reported by this meta-analysis, which can be described to be modest, at best.
Odds ratios for the individual SNPs ranged from 1.09 (rs645078) to 1.88
(rs34536443), with one SNP (rs4406273) deviating from this pattern with an OR of 4.32.
According to Stringer, Wray, Kahn and Derks (2011), ORs from GWA studies are
typically low to modest, although they may in fact be underestimates of the true
conditional odds ratios.
Despite these limitations, GWA studies should be considered foundational
research in the identification of novel candidate genes, which is especially important in
traits for which the biological etiology is unknown, such as the IMIDs.
Genetic Overlap Between Psoriasis and Crohn’s Disease. Wolf et al. (2008)
conducted a prospective case-control study in order to investigate the genetic overlap
between psoriasis and Crohn’s disease. Specifically, the authors analyzed the
contribution of CrD genetic determinants to psoriasis susceptibility. The authors
approached this study from the perspective that previous linkage studies have already
repeatedly identified the psoriasis disease susceptibility locus (PSOR1), as well as loci
PSORS2-10, as regions with overlapping susceptibility to other inflammatory conditions,
including CrD. Therefore, 15 CrD susceptibility loci newly identified by genome-wide
association analysis were assessed for significant disease associations with psoriasis
(Wolf et al., 2008). This study has been rated a 2+.
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Patients were recruited from within the United Kingdom via St. John’s Institute of
Dermatology in London (n=638), Glasgow Western Infirmary (n=211), and the
Dermatology Centre, University of Manchester (n=407). A total of 1,256 patients were
included in the study, 645 male and 611 female, all of northern European descent and
with onset of psoriasis vulgaris occurring before 40 years of age. Less than 1% of the
patients also had documented CrD. The patients were matched with 2,938 controls from
the Wellcome Trust Case-Control Consortium (WTCCC). Study approval was received
from three entities, the Guy’s and St. Thomas’ Hospitals Ethics Committee of Kings
College London, the Salford and Tafford Local Research Ethics Committee and North
Glasgow University Hospitals NHS Trust Local Research Ethics Committee. Informed
consent was obtained from all patients for the use of their DNA sample. Control
genotypes were obtained from publicly released data available at the WTCCC (Wolf et
al, 2008).
Patient DNA was typed using TaqMan assays and the frequencies of alleles for
both cases and controls were compared using a X2 test with one degree of freedom.
Regression analysis was conducted with PLINK software. Significant disease association
for three independent CrD markers, rs1203582 (OR=1.14; 95% CI 1.03 to 1.25),
rs6908425 (OR=1.26; 95% CI 1.12 to 1.42) and rs2836754 (OR=1.17; 95% CI 1.06 to
1.30), was observed among the psoriasis cases (Wolf et al, 2008). In other words, three
of the examined Crohn’s disease SNPs are significantly associated with psoriasis.
Interestingly, the marker that demonstrated the strongest effect, rs6908425, also maps to
a gene previously associated with type 2 diabetes (Wolf et al., 2008).
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Wolf et al. (2008) calculated false discovery rates (FDR), or the proportion of
discoveries that are false among all discoveries (Benjamini & Hochberg, 1995), for the
three significant SNP associations. The authors determined that all three significant
associations surpassed the 5% FDR threshold (P ≤ 0.01), with two SNPS (rs6908425 and
rs2836754) exceeding 1% FDR (P < 0.001). Additionally, Wolf et al. (2008) tested for
the presence of epistasis between the various disease-associated alleles using a case-only
test to assess for gene-gene interaction. Pair wise comparisons of all SNPS resulted in
non significant X2 values, however, using the same approach to test for interactions
between HLA-Cw*0602, the strongest determinant of disease risk from the PSOR1 locus,
against the individual SNPS, suggestive evidence for an interaction with rs12035082 was
generated (p= 0.02). Additional, larger patient cohorts would be necessary to validate, or
invalidate, this epistatic effect.
The major issues concerning case-control studies design are case-control
matching and presence of population stratification (Ghosh, 2007). Studies have shown
that allelic distributions may vary between different ethic populations. This highlights
the importance of selecting cases and controls with similar ethnic background in order to
ensure that false positive associations do not result. Wolf et al. (2008) argue that their
findings are unlikely to be due to population stratification, based on the fact that their
cases and controls have the same ethnic and geographical origin. The data generated by
WTCCC shows that the allele frequencies of SNPs rs12035082, rs6908425 and
rs2836754 are homogenous across the UK, further invalidating the plausibility that
associations are due to hidden population structure (Wolf et al., 2008).
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The results of this study lend additional evidence to suggest that individuals with
psoriasis are also predisposed to CrD. This highlights the pleiotropic effects of coautoimmunity, in which one gene influences two or more seemingly unrelated phenotypic
traits.
IL23R Association with Crohn’s disease, Celiac Disease and Psoriasis. In
2006, Duer et al. first identified an association of genetic markers in the interleukin-23
receptor (IL23R) gene, as well as the intergenic region between IL23R and IL122RB2,
with inflammatory bowel disease. Einarsdottir’s et al. (2009) objectives were to
determine if this association could be replicated with Swedish and Finnish patients with
IBD. The authors expanded their study to also assess IL23R’s association with two other
AI diseases with chronic inflammatory features, psoriasis and celiac disease. Einarsdottir
et al. (2009) utilized the Swedish and Finnish cohorts to also study the IL23R/psoriasis
association; the IL23R/celiac association was studied among Finnish, Hungarian, and
Italian populations. This study has been rated a 3.
Subjects for the IBD portion of the study were recruited from Karolinska
University Hospital in Stockholm. A total of 803 patients were selected based on
fulfillment of established clinical criteria, including endoscopic, radiological and
histopathological data. Of these 803 cases, 455 were patients with ulcerative colitis and
348 were patients with Crohn’s disease. Controls were randomly selected from
ethnically matched, unselected individuals (Einarsdottir et al., 2009).
The celiac disease subjects were recruited from Finland, Hungary, and Italy.
From Finland, 260 families with celiac disease were enrolled from the University of
Tampere. From this sample, 185 families had more than one individual affected with
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celiac disease (multiplex families), and 75 families had an affected father, mother and a
child (trios). The rest of the 165 families had only one affected family member. Celiac
disease was diagnosed mostly according to ESPGHAN criteria, however approximately
1% of the cases were diagnosed based on the presence of disease specific antiendomysial antibodies.
The Hungarian subjects consisted of 400 families, 204 of which were multiplex
families and 196 trios, plus 270 cases and 270 controls. The Italian dataset was
comprised of 139 cases and 198 controls. Although Einarsdottir et al. (2009) do not
describe the selection process for their Hungarian and Italian subjects in this publication,
readers are referred to other studies where this process was duplicated.
The Psoriasis dataset consisted of 255 Finnish families, 64 multiplex families and
191 trios, plus 385 affected individuals. One psoriasis patient from each family was
randomly selected and matched to a Finnish control. Again, the authors reference
another study for a description of the selection process.
Eight SNP markers were selected based on Duerr’s et al. (2006) study. All
genotyping took place at the MAF core facility in Karolinksa Institute, Stockholm,
Sweden. The case-control IBD dataset replicated the Duerr et al. (2006) findings with a
power of approximately 89%. Of the 8 SNPs assessed, SNP rs11465804*G demonstrated
the strongest association for the combined dataset including both CrD and UC (p=0.002,
OR=0.42). Marker rs1004819 also indicated a strong association with Crohn’s disease
in the Swedish population (p=0.006, OR=1.43) (Einarsdottir et al., 2009).
Central to linkage studies is the logarithm of odds (LOD) score analysis (Nyholt,
2000). The authors used this calculation to estimate whether the observed degree of
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concordance of IL23R markers between family members with celiac disease, indicates
signification genetic linkage between the two (Nyholt, 2000). LOD scores greater than 3
traditionally indicate that within the marked region, there is the presence of one or more
gene loci that influence the phenotypic trait; in other words, a LOD score of 3+ indicates
1000 to 1 odds that the linkage being observed did not occur by chance. This is
considered to be significant linkage (Nyholt, 2000). The Finnish families demonstrated
significant linkage for celiac disease (lod=3.24, p=0.00006, 135 individuals), while the
Hungarian families did not (lod=0.4, p=0.08, 132 individuals) (Einarsdottir et al., 2009).
Additionally, none of the celiac disease case-control datasets demonstrated significant
association to any of the IL23R markers (Einarsdottir et al., 2009).
The psoriasis studies also revealed mixed results. Fifty-one of the 255 Finnish
families with psoriasis were informative for linkage, yielding a LOD score of 0.83
(p=0.03). However, despite the low score, an association of IL23R with psoriasis was
confirmed in the Finnish case-controls. The authors suggest that polymorphisms in both
IL23R and IL12B, which encodes part of the IL23 cytokine, may collectively be more
important for susceptibility to psoriasis, than is either on their own (Einarsdottir et al.,
2009). As such, Einarsdottir et al. (2009) call attention to the fact that anti-IL12/IL23
antibody treatments improve psoriasis symptoms, which supports their argument that
multiple components exist in the pathway of this disease.
2.5 Population Based Studies
Psoriasis and Celiac Disease. Bhatia, Millsop, Debbaneh, Koo, Linos and Liao
(2014) conducted a meta-analysis of population-based studies examining the cooccurrence of psoriasis and celiac disease, investigations of celiac disease antibody
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markers in psoriatic cohorts, and clinical trials examining the therapeutic benefit of a
gluten free diet (GFD) in patients with psoriasis. The objective of this analysis was to
examine the evidence that patients with psoriasis are at an increased risk for celiac
disease and to also review studies evaluating the impact of a GFD on psoriasis
improvement (Bhatia, Millsop, Debbanch, Koo, Linos & Liao, 2014). This study has
been rated a 1+.
The authors searched the MEDLINE database via PubMed for articles between
1960 and 2012, and conducted a manual bibliographical search to identify additional
studies that warranted inclusion; 23 articles in total met their criteria. Meta-analysis was
performed in STATA using a random effects model (Bhatia et al., 2014).
Three population studies were reviewed, all of which demonstrated that patients
with psoriasis are at an increased risk for celiac disease (Bhatia et al., 2014). Fourteen
studies related to serological celiac disease markers in psoriasis patients were reviewed.
Of these fourteen, nine studies reported a positive association between celiac disease
markers, while seven did not find statistically significant evidence for an association.
Bhatia et al. (2014) caution that the findings in the latter seven studies may be related to
small study size and lack of control groups.
Further, Bhatia et al.’s analysis demonstrated a statistically significant relative
risk of testing positive for IgA anti-gliadin antibody (AGA) in patients with psoriasis, as
compared to control subjects (ORtotal = 2.36; 95% C.I. 1.15-4.83) (Bhatia et al., 2014).
The authors are 95% confident that the odds are between 1.15 and 4.83 greater for an
individual with psoriasis to test positive for IgA AGA than for an individual without
psoriasis.
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Finally, the authors examined a number of studies that considered the effect of a
GFD on psoriasis severity. Six studies demonstrated that patients with psoriasis, with
either elevated AGA and/or tTG, showed improvement in psoriatic lesions after a GFD.
One study utilized a pre- and post-GFD Psoriasis Area Severity Index (PASI) score to
evaluate changes, revealing a 73% improvement. In this same study, AGA levels were
lower in 82% of the psoriasis patients (Bhatia et al., 2014). The authors highlight an
interesting result from this study; for the patients with both psoriasis and elevated AGA
levels, and who experienced improvements after the GFD, all also had normal
histological results in their pre-GFD duodenal biopsies. The authors conclude that a GFD
may be beneficial in patients with psoriasis and gluten-sensitivity (marked by elevated
AGA levels) even in the absence of biopsy-confirmed celiac disease (Bhatia et al., 2014).
The results of this meta-analysis demonstrate that both epidemiological and
clinical studies suggest an association between psoriasis, celiac disease, and celiac
disease markers. The authors conclude that health care providers should screen their
patients with psoriasis for symptoms of celiac disease, including diarrhea, flatulence,
fatigue and history of iron-deficiency anemia. Positive findings should flag providers to
then run serological tests for celiac associated antibodies (Bhatia et al., 2014).
Association of Psoriasis with Other Autoimmune Diseases. Wu, Nguyen,
Poon and Herrinton (2012) conducted a retrospective cohort study in order to examine
the association between psoriasis and 21 autoimmune diseases that share common
pathogenetic mechanisms, including celiac disease, Crohn’s disease and RA. The authors
also looked closely at patients with both psoriasis and psoriatic arthritis, hypothesizing
that these individuals would be even more likely to have an additional autoimmune
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disorder, compared to individuals with psoriasis alone (Wu, Nguyen, Poon & Herrinton,
2012). This study has been rated a 2+.
The study population was formed from patients who were members of the Kaiser
Permanente Southern California (KPSC) health plan from January 1, 2004 to February
28, 2011. Inclusion criteria were as follows: patients of age 0 to 100 years, with at least
one year of enrollment during the designated timeframe, and two or more inpatient or
outpatient diagnoses codes for psoriatic disease (International Classification of Diseases,
Ninth Revision (ICD-9), code 696.0-1), two codes for psoriasis only (ICD-9 code 696.1),
2 codes for psoriatic arthritis (ICD-9 code 696.0), or codes for both psoriasis and
psoriatic arthritis (one code each of 696.1 and 696.0) (Wu et al., 2012).

The comparison

group was formed by randomly selecting individuals without psoriatic disease from
KPSC at a ratio of five to one, and matching these individuals to the cohort by gender,
year of birth (± one year) and length of enrollment (± one year) from the first date.
25,341 patients with psoriatic disease were ultimately matched with 126,705 control
subjects (Wu et al., 2012).
Data was collected from the clinical and administrative databases of KPSC, to
include patient demographics, inpatient/outpatient visits, and additional diagnoses (the
outcome variables) for the 21 autoimmune diseases included in this study (Wu et al.,
2012). Statistical analysis was conducted using SAS Enterprise Guide, version 4.3. The
association between each autoimmune disease (the outcomes) and psoriasis (the
exposure) was calculated using X2 test. Conditional logistic regression was performed to
the compare the risk of autoimmune disease between psoriatic disease and the matched
control subjects (Wu et al., 2012).
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Psoriasis was positively associated with 17 of the 21 studied AI diseases, with 14
of these associations being statistically significant (Wu et al., 2012). The strongest
association was with RA (OR=3.6; 95% CI 3.4-3.9). Patients with psoriasis were 3.6
times more likely to have RA, as compared to persons without psoriasis. Celiac disease
was the third strongest association (OR=2.3; 95% CI 1.6-3.2), and Crohn’s disease was
the fifth strongest association (OR=1.8; 95% CI 1.5-2.2) (Wu et al., 2012). Combining
patients with both psoriasis and psoriatic arthritis demonstrated a significantly increased
OR with most autoimmune diseases. And, individuals with psoriatic disease were more
likely to have at least two (OR=1.6; 95% CI 1.5-1.7) or three (OR=1.9; 95% CI 1.6-2.4)
immune-mediated diseases compared to persons without psoriatic disease (Wu et al.,
2012). These findings suggest that patients with psoriasis are more likely than control
subjects to be given the diagnosis of an additional autoimmune disease. The authors
conclude their study by recommending that the evaluation of patients with psoriasis for
other autoimmune diseases may be warranted as part of their health care (Wu et al.,
2012).
Some of the limitations that are characteristic to cohort studies may have been
present in this study. First, diagnostic information was culled from databases and prior
diagnostic codes, neither of which were validatable (possible information bias). Second,
due to their medical issues, the patients with psoriasis may have had more frequent
contact with the health care system resulting in a greater opportunity to record associated
diseases, as compared to the control group. On this point, and in defense of the study, it
was conducted over a sufficient length of time that providers should have had ample
opportunity to recognize additional diagnoses, even in the cohort group who may have
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had fewer health care management needs. Third, a lack of data regarding possible
confounders did not allow the authors to make adjustments in relation to the outcomes.
Finally, another limitation to this study is that is was restricted to the geographic location
of southern California.
Psoriasis and Co-morbidities, Analysis of Health Insurance Data in
Germany. Augustin, Reich, Glaeske, Schaefer and Radtke (2010) conducted a
retrospective cohort study using a large sample of German health insurance information.
The authors’ objective was to evaluate the prevalence of co-morbidities in patients with
psoriasis, particularly those related to metabolic syndrome. Given the existing evidence
that points to a relationship between psoriasis and other IMIDs, the authors also evaluated
the association between psoriasis and RA and Crohn’s disease (Augustin, Reich, Glaeske,
Schaefer & Radtke, 2010). This study has been rated a 2+.
Patients with psoriasis were first identified from a pool of 1.3 million individuals
who were insured by a German nationwide statutory health insurance during the year
2005. Individuals were counted as cases if they had at least one visit to a healthcare
provider documented with the World Health Organization (WHO) ICD-10 codes marking
psoriasis (L40). Individuals from this dataset without a diagnosis for psoriasis were
marked as controls. In total, 33,981 individuals were identified for having psoriasis and
1,310,090 individuals without psoriasis served as the controls (Augustin et al., 2010).
The Pharmafacts Research Institute, located in Berlin, Germany, performed data
analysis. Prevalences were calculated for co-morbidities of interest and the prevalence
ratio was determined by comparing the prevalence rate of the psoriatic group to the non-
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psoriatic group. Corresponding confidence intervals were computed by a general method
based on constant X2 boundaries (Augustin et al., 2010).
Individuals with psoriasis showed increased rates of co-morbidities compared to
individuals without psoriasis (Augustin et al., 2010). Metabolic syndrome was more
frequently diagnosed in those with psoriasis (PR=2.86; 95% CI 2.21-3.71). Moreover,
the medical conditions that collectively contribute to metabolic syndrome were also
significantly more common among patients with psoriasis on an individual level:
diabetes mellitus (PR=2.02; 95% CI 1.96-2.08); hyperlipidemia (PR=1.75; 95% CI 1.721.78); arterial hypertension (PR=1.73; 95% CI1.71-1.76); and obesity (PR=1.72; 95% CI
1.68-1.76) (Augustin et al., 2010).
While not of direct interest to this IMID project, the aforementioned conditions
provide additional context when considering the prevalence rates that Augustin et al.
(2010) calculated for RA (PR=3.84; 95% CI 3.43-4.31) and Crohn’s disease (PR=2.06;
95% CI 1.84-2.31) among patients with psoriasis. Rheumatoid arthritis and Crohn’s
disease ranked first and third in prevalence, respectively, among all the co-morbidities
studied. This is noteworthy when one considers that approximately 34% of adults in the
United States could be characterized as having metabolic syndrome (CDC, 2009), the
second highest prevalent co-morbidity from this study. Whereas health care providers
routinely screen for the components of metabolic syndrome (hypertension, cholesterol
levels, BMI and diabetes), RA and Crohn’s disease are not routinely screened for,
although perhaps they should be, especially in patients with psoriasis. Augustin et al.
(2010) do not directly make this recommendation, however, the authors make two
significant statements: (1) the results of this study strongly support the association of
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psoriasis and systemic chronic inflammatory diseases and (2) these findings should
influence the healthcare management of patients with psoriasis by clinicians.
The limitations of this study are similar to those previously mentioned in the
review of the Wu et al. (2012) study; possible information bias, lack of clinical data
allowing for the adjustment of outcomes as related to potential confounders (smoking
status or psychosocial factor), possible increased health care visits for psoriatic patients
versus the controls, and geographic area.
Psoriasis and Co-morbidities, Analysis of a National Database in Taiwan.
Tsai et al. (2011) conducted a study similar to Augustin et al. (2010). A retrospective
cohort study (with controls) was performed using the Taiwan National Health Insurance
Research Database (NHIRD) during 2006. The authors’ aim was to study the prevalence
of comorbidities in patients with psoriasis. This large database, representing 99% of the
total Taiwanese population, was utilized with the hopes of capturing less commonly
assessed disease associations such as with the autoimmune disorders rheumatoid arthritis
and Crohn’s disease (Tsai et al., 2011). This study has been rated a 2+.
The NHIRD covers all benefit claims for approximately 22 million Taiwanese
enrollees, and was established in 1995 by the National Health Research Institute and the
National Health Insurance Bureau for the promotion of research on present and emerging
medical issues in Taiwan (Tsai et al., 2011). This database was utilized to identify
patients with at least one outpatient visit or admission claim with an ICD-9 diagnosis for
psoriatic arthropathy (696.0) or psoriasis (696.1), resulting in a sample of 51,800 cases.
75.08% of the patients were identified at departments of dermatology, 3.42% at
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departments of immunology/rheumatology, and 21.51% from “other,” non-specified
departments (Tsai et al., 2011).
The psoriasis cases were then further classified by severity. Individuals who had
received any systemic therapy or phototherapy in 2006 were designated as moderate to
severe (sPsO, n=9,063), while those who had not were designated as mild psoriasis
(mPsO, n=36,252). The control group (n=207,200) was established by identifying
patients without diagnoses for either psoriatic arthropathy or psoriasis, and matched at a
4:1 ratio based on age, gender and residential area (Tsai et al, 2011). Co-morbidities
were defined based on at least three claims for an outpatient visit or one hospitalization
with a principal/secondary diagnosis within one year of the index date, 2006 (Tsai et al.,
2011).
The authors calculated prevalence associated with psoriasis and co-morbidities
between cases and controls using relative risk (RRs) and 95% confidence intervals (CI)
based upon a Cox proportional regression model (Tsai et al., 2011). The authors found
that patients with psoriasis had a total increased risk for depression (RR=1.50; 95% CI
1.39-1.61, p-value >.0001), hypertriglyceridemia (RR=1.61; 95% CI 1.54-1.68, p-value
>.0001), hypertension (RR=1.51; 95% CI 1.47-1.56, p-value >.0001), diabetes (RR=1.64;
95% CI 1.58-1.70, p-value >.0001), cardiovascular disease (RR=1.32; 95% CI 1.26-1.37,
p-value >.0001) and malignancies of the digestive organs and peritoneum (RR=1.57;
95% CI 1.41-1.74, p-value >.0001).
Interestingly, in this study patients with moderate to severe psoriasis were found
to have 10.25 times the risk for RA (95% CI 8.20-12.81), and patients with mild psoriasis
were found to have 1.56 the risk for RA (95% CI 1.33-1.83) compared to patients without
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psoriasis. The total risk for RA among all patients with psoriasis was calculated to be
3.02 times that for non-psoriatic patients (95% CI 2.68-3.41). When compared to the comorbidities listed in the previous paragraph, RA by far demonstrates the highest risk
among patients with psoriasis. These results echo the findings published in the Augustin
et al. (2010) study.
Finally, the percentage of psoriatic patients with Crohn’s disease was actually
lower in this study as compared to patients without psoriasis, although the authors state
that this lower percentage did not show statistical significance. Tsai et al. (2011)
postulate that the difference in association between psoriasis and Crohn’s disease may
relate to ethnic differences in shared genetic susceptibility loci or, alternatively, in the
presence of disease protection loci.
The relevance of these findings is significant, particularly with regards to patients
with moderate to severe psoriatic disease. Tsai et al. (2011) conclude their study by
suggesting that clinicians should take into consideration the association of co-morbidities
when evaluating the potential burdens of psoriatic patients and designing effective health
care management plans.
A Comparison of Prevalence Ratios in Patients with Psoriatic Arthritis and
Psoriasis. Through another retrospective cohort study, Makredes, Robinson, Bala and
Kimball (2009) investigated whether patients with psoriatic arthritis (PsA) carry a higher
AI disease burden than patients with psoriasis (PsO) alone. These authors utilized the
IMS Health Integrated Administrative Claims Database (Norwalk, CT) to compare the
prevalence of seven AI disorders among patients with PsA and PsO (Makredes,
Robinson, Bala & Kimball, 2009). The AI disorders were chosen based on a lack of
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overlapping dermatologic or rheumatologic clinical manifestations to psoriasis or
psoriatic arthritis (Makredes et al., 2009). Crohn’s disease and inflammatory bowel
disease were among the seven AI disorders examined. This study has been rated a 2+.
At the time of this study, the IMS Health Integrated Administrative Claims
Database covered approximately 11 million individuals. From this dataset, patients were
selected on the basis of age greater than 18, with at least one medical service visit of any
kind between the dates of January 1, 2001 and December 31, 2002, and indicating at least
one ICD-9 psoriasis code (696.0-1). 25,556 individuals were identified based on these
criteria. These individuals were then classified into two clinical subsets, individuals with
arthritic manifestations (PsA; ICD-9 696.0, n=3066) and those without arthritic
manifestations (PsO; ICD-9 696.1, n=22,499). Individuals in the PsO group were not
allowed to also have the presence of a PsA diagnostic code (Makredes et al., 2009).
Control groups for both subtypes were selected at a 3:1 ratio, matching for at least
one medical encounter, age (within two years), sex, US census region, and length of
previous medical insurance coverage. The control subjects could not have any ICD-9
psoriasis code in their records during the two year period of study (Makredes et al.,
2009).
The case identification for other AI disorders required at least one medical claim
for the ICD-9 diagnostic code of interest. The occurrence rates for these AI diseases
were compared among control subjects, the PsO group, and the PsA group using the
prevalence ratio (PR) statistic. A 95% CI was estimated with the Mantel-Haenszel test
(Makredes et al., 2009). The authors found statistically significant trends between
several AI disorders and both psoriasis subtypes, with the strongest relationships
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belonging to PsA. Of particular interest, patients with PsO had an increased PR
associated with Crohn’s disease (1.6; 95% CI 1.4-2.0) and inflammatory bowel disease
(1.4; 95% CI 1.2-1.6) when compared to individuals without psoriasis. Demonstrating an
even stronger relationship, patients with PsA also carried an increased risk for Crohn’s
disease (2.1; 95% CI 1.3-3.3) and inflammatory bowel disease (1.8; 95% CI 1.3-2.5).
Based on these findings, Makredes et al. (2009) reach three conclusions. First, the
data supports the premise that PsA and PsO are associated with the development of other
AI diseases. Second, patients with PsA and PsO appear to be at greater risk for GI
diseases. Third, these findings suggest that evaluating psoriatic patients in a prospective
manner for other associated AI disorders may be important toward the patient’s long-term
health outcomes (Makredes et al., 2009).
Psoriasis, Psoriatic Arthritis and Increased Risk of Crohn’s Disease in US
Women. Li, Han, Chan and Qureshi (2013) performed a prospective cohort study in
order to evaluate the association between psoriasis, psoriatic arthritis and incident UC
and CrD among women in the US. The authors utilized two large, ongoing prospective
studies of US women for their assessment, the Nurses’ Health Study (NHS) and the NHS
II (Li, Han, Chan & Qureshi, 2013). Collectively, these two datasets provide over 30
years of biennially updated data on diagnoses and lifestyle. This study has been rated a
2+.
The NHS enrolled 121,701 US female nurses aged 30-55 years in the year 1976
after a mailed questionnaire was completed detailing medical history and lifestyle factors.
In 1989, NHS II was established when a similar questionnaire was completed by 116,430
US female nurses, aged 25-42 years. The information from both cohorts has been
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undated every two years, with a response rate exceeding 90%. In 2005 and 2008,
respectively, NHS and NHS II enrollees were questioned about physician-diagnosed
psoriasis, psoriatic arthritis, and the diagnosis date. Self-reported psoriatics were
confirmed by using the Psoriasis Screening Tool (PST); psoriatic arthritis was confirmed
through the PsA Screening and Evaluation (PASE) questionnaire (Li et al., 2013).
Participants who reported a diagnosis of UC or CrD in consecutive NHS and NHS II
responses were asked to complete a supplementary questionnaire and for permission to
review their medical records. Two gastroenterologists, who were blinded to exposure,
reviewed these medical records; diagnosis for UC or CrD was confirmed if the original
diagnosis was established through the fulfillment of standardized criteria (Li et al., 2013).
A critical aspect of this study was confirmation that the psoriasis diagnosis preceded the
diagnosis for either UC or CrD (Li et al., 2013).
Statistical analysis was performed using SAS and all p-values were two tailed.
The following calculations were made: (1) time dependent Cox proportional hazards
model stratified by age for the estimation of relative risks (RRs) and 95% CI; (2)
multivariate analysis with adjustments for age, BMI, smoking, alcohol intake, physical
activity, and use of postmenopausal, oral contraceptive, aspirin and NSAID drugs; (3)
between-studies heterogeneity and overall association from random effects (Li et al.,
2013).
Total number of participants in this study was 174,476 (78,211 from NHS and
96,265 from NHS II). 2,755 women reported a diagnosis of psoriasis at baseline (1996
for NHS and 1991 for NHS II). An additional 512 women from NHS and 1,122 women
from NHS II reported psoriasis over follow-up through 2005.
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In NHS, there were 72

confirmed cases of CrD and 116 cases of UC from 1996 to 2008. In NHS II, there were
116 confirmed cases of CrD and 166 cases of UC from 1991 to 2007. Li et al. (2013)
report that women with psoriasis had an increased risk of developing CrD with a
multivariate adjusted RRs of 4.05 (95% CI 1.75-9.38) in NHS and 3.76 (95% CI 1.827.74) in NHS II. The pooled analysis demonstrated that psoriasis was associated with a
RR of 3.86 (95% CI 2.23-6.67) for developing CrD (Li et al., 2013). The authors did not
find a statistically significant increased RR for development of UC in women with
psoriasis in either database (Li et al., 2013).
The authors also examined the risk for CrD among women with both psoriasis
and psoriatic arthritis. In addition to observing a particularly high risk of CrD among
female patients with psoriasis and psoriatic arthritis (RRpooled=6.54; 95% CI 2.07-20.65),
Li et al. (2013) also observed a higher risk associated with longer duration and earlier
onset of psoriasis. Together, these findings offer additional evidence in the support of
common underlying mechanisms between psoriasis and CrD. Because the study was
limited to US female healthcare workers, additional research should be conducted in
other populations to confirm results.
Psoriasis Associated with UC and Crohn’s Disease. Cohen, Dreiher and
Birkenfeld (2009) investigated the relationship between psoriasis and the components of
inflammatory bowel disease, UC and CrD, through a case-control study that utilized the
large medical dataset of Clalit Health Services (CHS). The authors theorized that as both
UC and CrD are associated with inflammation, and that both diseases are treated with and
respond to similar medications, that these inflammatory bowel diseases may each be
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independently associated with psoriasis (Cohen, Dreiher & Birkenfeld, 2009). This study
has been rated a 2+.
Clalit Health Services is the largest healthcare provider organization in Israel,
serving a population of approximately 3,800,000 enrollees at the time of this study. This
database receives continuous, real-time information from pharmaceutical, medical and
administrative operating systems, facilitating epidemiological studies via the Clalit
Research Institute. Cohen et al. (2009) identified patients from this database who had at
least one documented diagnosis for psoriasis by a CHS community provider or through
hospital discharge diagnosis. The authors matched the cases with controls, also from
CHS, at a 2:1 ratio. Patient cases numbered 12,502; cohorts without psoriasis were
matched by sex and age, equaling 24,285 patients (Cohen et al., 2009). The authors also
extracted information regarding diagnoses for UC or CrD, as well as patient use of the
following three anti-TNF-α drugs, infliximab, etanercept and adalumumab.
Statistical analysis was performed using SPSS software, version 13. The authors
compared the proportion of patients with IBD between patients with and without
psoriasis. For categorical parameters between the groups, chi-squared tests were
performed, while t-tests were used for comparison of continuous variables. Logistic
regression was then used to measure the association between psoriasis and UC and CrD
in a multivariate analysis of variables stratified for age, gender, socioeconomic status
(SES), and smoking status (Cohen et al., 2009).
The prevalence of both UC and CrD was significantly increased in patients with
psoriasis compared to those without psoriasis. The association of UC and psoriasis
compared with controls was statistically significant in patients 20-39 years old (OR=5.78;
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95% CI 1.81-18.5, p-value ≤ 0.001), in male patients (OR=1.78; 95% CI 1.11-2.82, pvalue < 0.05), and in non-smokers (OR=1.99; 95% CI 1.34-2.95, p-value ≤ 0.001). The
multivariate analysis findings indicate that ulcerative colitis was significantly associated
with a co-diagnosis for psoriasis (OR=1.65; 95% CI 1.15-2.33), as well as with age, sex
and SES of the patient (Cohen et al., 2009).
The association of CrD and psoriasis compared with controls demonstrated
similar, but more widespread results. For example, while UC showed statistical
significance with patients aged 20-39 years, CrD was associated with patients in both the
20-39 (OR=6.05; 95% CI 2.91-12.6) and 40-59 (OR=2.14; 95% CI 1.13-4.05) age
brackets. A significant association was also found for patients with psoriasis and CrD for
both genders, with a higher burden on females (OR=4.60; 95% CI 2.50-8.45) versus
males (OR=1.66; 95% CI 1.02-2.71), as well as in smokers (OR=2.78; 95% CI 1.266.16) and non-smokers (OR=2.48; 95% CI 1.61-3.80), compared to controls. The
multivariate analysis indicates that, likewise to UC, CrD is significantly associated with
co-disease of psoriasis (OR=2.49; 95% CI 1.71-3.62), age, sex and SES (Cohen et al.,
2009).
As with other epidemiological studies utilizing secondary data, the major
limitation of this study was an inability to confirm patient diagnoses, either for psoriasis,
CrD and UC. Misclassification of information cannot, therefore, be completely ruled out.
However, the authors stand by the strength of the CHS data warehouse, which sources all
data through a universal EHR system, and capitalizes upon the expertise of Israel’s
practitioners (Cohen et al., 2009). In summary, the findings of this study cast additional
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support for a significant association between psoriasis and the inflammatory bowel
diseases.
Psoriasis and Celiac Disease. Three of the authors from the previous study
Birkenfeld, Dreiher, and Cohen, collaborated with a fourth author, Weitzman (2009) to
investigate the association between psoriasis and celiac disease. With the exception of
the evaluated outcome (celiac disease), this study mirrored the one previously described.
This case-control study also utilized the large medical dataset of Clalit Health Services
(CHS) and has been rated a 2+.
This study included 12,502 patients with psoriasis who were greater than twenty
years old and 24,285 patients without psoriasis who were matched on a 2:1 ratio based on
age and sex (Birkenfeld, Dreiher, Weitzman & Cohen, 2009). The prevalence of CD
was greater in patients with psoriasis than in controls. The association between psoriasis
and CD was further evaluated by age, 20-39 years, 40-59 years and 60-110 years. In all
age groups, the association was significant, however the strength of the association
decreased with increasing age. Additionally, an association was prominent among
women and among those of intermediate SES (Birkenfeld et al., 2009).
There were neither significant confounding factors noted among age, sex or SES,
nor effect modification by any covariate. The multivariate logistic regression analysis
revealed that psoriasis was associated with CD (OR=2.73; 95% CI 1.65-4.53, p-value <
0.001). The strength of the associated remained significant after controlling for age, sex
and SES (OR=1.79; 95% CI 1.03-3.10, p-value = 0.039).
The authors conclude that healthcare providers should be aware of the possible
association between psoriasis and CD. Active screening for CD may lead to a diagnosis

59

of latent CD in patients with other autoimmune diseases, particularly in those with
psoriasis (Birkenfeld et al., 2009).
Serology of Celiac Disease in Psoriasis. Damasiewicz-Bodzek and
Wielkoszynski (2008) investigated whether patients with psoriasis also had increased
levels of CD-associated antibodies compared to healthy controls, implicating gluten
intolerance. The authors measured titres of IgA and IgG antibodies against tissue
transglutaminse from guinea pig liver (a-GP-tTG), of IgA antibodies against human
recombinant tissue transglutaminase (a-h-r-tTG IgA), of anti-gliadin antibodies (AGA
IgA and AGA IgG), as well as anti-endomysial antibodies for IgA (IgEmA) in patients
with and without psoriasis. The aim of this study was to demonstrate whether there is an
increase in the frequency of those markers of CD in patients with psoriasis
(Damasiewicz-Bodzek & Wielkoszynski, 2008). This cross sectional study has been
rated 3.
The cases were identified based on hospital admission for intensified psoriatic
skin lesions in the Upper Silesia (Poland) region. A total of 67 patients were included; 27
females and 40 males whose mean PASI score measured 25.9 ± 14.9. Patients with
psoriatic arthritis and other diseases were excluded from the study. Controls without
psoriasis were matched for sex and age. Patients with a family history for either psoriasis
or celiac disease were excluded from the control group. The study commenced prior to
any anti-psoriasis treatment was started, and all cases and controls were on glutencontaining diets. Blood samples were collected from both groups, following an overnight
fast (Damasiewicz-Bodzek & Wielkoszynski, 2008).
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Approximately 6% of psoriatic patients screened positive for four serologic
markers, while 28.1% had three serologic markers positive, and 17.7% had two serologic
markers positive. The authors proceeded to test the data in triplicate (KolmogorovSmirnov, U Mann-Whitney and Wald-Wolfowitz’s) revealing that patients with psoriasis
have statistically significant higher mean levels of antibodies against tissue
transglutaminase from guinea pig liver (a-GP-tTG) for both IgA (p <0.001, P=0.000000
and p=0.000006, respectively) and IgG (p < 0.001, p=0.000001, and p=0.01) than do
patients without psoriasis. Furthermore, in 46% of the cases for IgG, and as much as
66% of the IgA cases, titres of antibodies were higher than the 90th percentile of the
control values. Patients with psoriasis also had higher mean levels of IgA antibodies
against the human recombinant tissue transglutaminase (p < 0.001, P = 0.036 and
p=0.002); 54% of the cases were higher than the 90th percentile of the control values.
The titres of antibodies against gliadin between psoriatics and controls were increased at
statistically significant levels for IgA (p < 0.001, p = 0.000000 and p = 0.0005), but not
for IgG (p > 0.01, p = 0.75, and p = 0.244). And no anti-endomysial antibodies for IgA
were found in any serum, either cases or controls. (Damasiewicz-Bodzek &
Wielkoszynski, 2008).
The authors also used the Spearman rank correlation to test the association
between the examined antibodies and the PASI score. Concentrations of a-h-r-tTg IgA
positively correlated with concentrations of a-GP-tTG IgA, a GP-tTg IgG and AGA IgA.
Concentrations of a-h-r-tTG IgA, a-GP-tTG IgA and AGA IgA also positively correlated
with PASI (Damasiewicz-Bodzek & Wielkoszynski, 2008).

Given the widely accepted

use of these serologic antibody tests to diagnose celiac disease, these results suggest that
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there is an association between psoriasis and asymptomatic celiac disease/gluten
intolerance (Damasiewicz-Bodzek & Wielkoszynski, 2008).
Early Detection of Crohn’s Disease in Psoriasis. Radtke et al. (2015) published
the results of a German interdisciplinary partnership whose objective was to develop
screening algorithms for dermatologists for twelve different comorbidities in patients
with psoriasis, including chronic inflammatory bowel disease. This effort stemmed from
a national survey on psoriasis care in 2005, which indicated deficits in care for those with
psoriasis in Germany. As a result, the German “National Healthcare Goals in Psoriasis
2010-2015” defined early detection of comorbidities in psoriatic patients as a nationwide
goal of dermatological care (Radtke et al., 2015). At the 2010 Healthcare Research
Conference, the establishment of a methodological basis for the implementation of this
health care goal was tasked to a working group of the conference and confirmed by the
German Society of Dermatology (DDG) and the Professional Association of German
Dermatologists (BVDD). The goal of this work was to develop descriptive and practical
screening algorithms, thereby providing dermatologists with the decision-making tools
required for early diagnosis of comorbidities (Radtke et al., 2015). This consensus paper
would be considered expert opinion, and as such this study has been rated a 4.
The task was approached from a three-stage process. First, a national consensus
conference on psoriasis established a definition for the requirements, areas of application,
conception, and methodology of an agreed screening algorithm (Radkte et al., 2015).
Second, a literature search was conducted to investigate the most relevant comorbidities
associated with psoriasis, as well as possible screening approaches. More than 2,000
publications were included in the appraisal and evidence for the use of screening
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parameters for the individual comorbidities was compiled (Radtke et al., 2015). Finally,
an interdisciplinary group of the National Healthcare Conference evaluated the
algorithms according to content-related, methodological, and formal characteristics, as
well as practicability. The algorithms were then adopted through a Delphi consensus
process (Radtke et al., 2015).
Since dermatologists in Germany are the most frequently consulted provider for
patients with new onset psoriasis, it was considered imperative that these providers
facilitate early detection of associated comorbidities. The twelve comorbidities chosen
for screening in patients with psoriasis included arterial hypertension, dyslipidemia,
obesity, diabetes mellitus, metabolic syndrome, nonalcoholic steatohepatitis, depression,
nicotine abuse, alcohol abuse, psoriatic arthritis, malignant lymphoma and chronic
inflammatory bowel disease (Radtke et al., 2015). The following target parameters for
screening were identified for IBD.
Table 2.2 Screening Parameters for IBD
Chronic diarrhea (> 3 bowel movements
per day and > 4 weeks) and ≥ 1 of the
following symptoms:

Blood in stool
Pain or bleeding during intestinal
peristalsis
Painful defecation (DD: differentiation
from anal fissure, hemorrhoids)
Abdominal pain especially in the right
lower abdomen
Pyoderma gangrenosum, erythema
nodosum, oral aphthae
Temperature > 37.8 °C (100 °F) during the
past 7 days
Weight loss
Anal fistula, anal fissures, or perirectal
abscesses or other fistulas (e.g. enterovesical fistula)
Ocular involvement: uveitis or iritis
Arthritis or arthralgia
(Radtke et al., 2015)
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The recommended interval for follow-up examinations for individuals with mild
psoriasis is every 12 months, and every 6 months for individuals with severe psoriasis
(Radtke et al., 2015). The collaborative efforts of DDG and BVDD underscore the
importance of primary prevention and health promotion in at risk groups, particularly in
those with psoriasis.
2.6 Synthesis of Findings
Of the fourteen articles reviewed for this evidence-based project, ten investigated
the association of psoriasis with Crohn’s disease, seven with celiac disease, and four with
rheumatoid arthritis. Among the four genetic studies with varying research
methodologies, a pattern emerges that lends support for an association between psoriasis
and the three AI diseases under investigation. Tsoi et al. (2013) demonstrated that 39
psoriasis susceptibility loci are known today, ten of which overlap with Crohn’s disease,
nine with celiac disease, and five with rheumatoid arthritis. And, a significantly
increased multiple AI disease risk was found to be associated with the CD226 Gly307Ser
t allele rs763361, a gene that has been reported to be associated with psoriasis, celiac
disease, and rheumatoid arthritis (Qui et al., 2013). The Wolf et al. (2008) study implies
that three Crohn’s disease SNPs are significantly associated with psoriasis. Finally, the
results of Einarsdottir’s et al. (2009) study suggest that there is an association of IL23R
with Crohn’s disease, psoriasis and celiac disease.
A similar pattern appears within the population based studies. Among those
focusing on psoriasis and celiac disease, two studies demonstrate a positive association
between psoriasis and celiac disease (Birkenfeld et al., 2009; Wu et al., 2012), while two
more also demonstrate that patients with psoriasis tend to exhibit the presence of
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serological markers associated with celiac disease (Bhatia et al., 2014; DamasiewiczBodzek & Wielkoszynski, 2008). Further, evidence suggests that a GFD, typically
prescribed to patients with celiac disease, may lead to resolution or improvement of
psoriatic lesions (Bhatia et al., 2014).
Six population-based studies investigated the association between psoriasis and
Crohn’s disease. With the exception of one study (Tsai et al., 2011), the other five
studies showed statistically significant associations between the two AI diseases
(Augustin et al., 2010; Cohen et al., 2009; Li et al., 2013; Makredes et al., 2009; Wu et
al., 2012). It is also very compelling that dermatologists in Germany have
acknowledged the relationship between psoriasis and IBD, recommending that providers
screen annually for IBD in moderate cases and bi-annually in severe cases of psoriasis, in
order to promote best patient outcomes (Radtke et al., 2015).
With respect to psoriasis and rheumatoid arthritis, three population-based studies
highlight the relationship between these two AI diseases. Wu et al. (2012) found that
among 21 different AI disorders, RA held the strongest statistically significant
association with psoriasis. The Tsai et al. (2011) study found that the total risk for RA
among all patients with psoriasis was calculated to be 3.02 times that for non-psoriatic
patients. And, individuals with psoriasis showed increased rates of RA compared to
individuals without psoriasis in the Augustin et al. (2010) study.
2.7 Summary
While it is clear that the autoimmune puzzle is by no means complete, requiring
substantial and robust future research efforts, healthcare providers may be able to take
into consideration and utilize the information presently available, which is as follows.
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One, autoimmune disorders can take years to diagnose, primarily because symptoms may
present vaguely and also due to healthcare provider knowledge deficits about AI diseases
in general, and how they relate to one another. Two, earlier detection of autoimmune
diseases and initiation of treatment may improve patients’ long-term outcomes. Three,
individuals with one autoimmune disorder are more likely than the general population to
have one or more other AI diseases. Four, the most prevalent AI disease is psoriasis.
Five, psoriasis belongs to a subset of AI diseases called IMIDs, which includes celiac
disease, rheumatoid arthritis and Crohn’s disease. There is a genetic relationship among
these diseases. Six, individuals with psoriasis seem to have an increased risk of also
having celiac disease, rheumatoid arthritis and Crohn’s disease.
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Chapter 3
Project Design
3.1 Methods
Research indicates that individuals with psoriasis may be predisposed to the three
IMIDs of interest to this study, celiac disease, rheumatoid arthritis and Crohn’s disease.
The literature also suggests that health care providers would be prudent to evaluate
psoriatic patients in a prospective manner for these AI disorders in order to improve the
patient’s long-term health outcomes.
The purpose of this project is to conduct a substantive review of the literature and
conduct screening of primary care patients with psoriasis to determine early detection of
celiac disease, rheumatoid arthritis, and Crohn’s disease. The objective of this quality
improvement project is to administer a patient questionnaire to adult patients aged 18
years and greater with psoriasis, screening for signs and symptoms of celiac disease,
rheumatoid arthritis and Crohn’s disease. This quality improvement project was guided
by evidence provided by the literature search and synthesis, the methods based on the
Iowa Model of Evidence-Based Practice. The Iowa Model provided a guideline to
decrease barriers while instilling confidence in the new patient questionnaire. This
chapter will present the methods for conducting the project. A detailed process is
outlined for implementing the project, including a time frame, intervention, and data
management.
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3.2 Design
The project will implore a retrospective (chart review), one test design to
determine if the patient with psoriasis has been screened as noted by the provider
documentation. The provider will make a referral for further diagnostic testing or to a
specialist based on the patient questionnaire algorithm, which will be noted in the
provider’s documentation.
3.3 Instrument
To date, no individual screening tools have yet been validated as having sufficient
predictive ability for celiac disease, rheumatoid arthritis or Crohn’s disease. Diagnosis
for these AI diseases relies upon a combination of patient history, physical examination,
laboratory tests, imaging studies and biopsy (Pincus, Yazici & Sokka, 2009). Current
diagnostic algorithms are founded on the if/than approach: if these symptoms exist, and if
positive serologies or scans/biopsy are present, than we can conclude diagnosis. The
path to diagnosis still begins with a provider’s strong suspicion of disease.
For groups that have been identified to be at higher risk than the general
population for development of these AI diseases, including patients with psoriasis,
practitioners’ must have a simple tool that kindles suspicion, opens discussion, and
facilitates investigation at the earliest signs of possible disease. Patient questionnaires
used in clinical practice are effective toward collecting patient information, guiding
management, documenting change in status, assessing outcomes, and improving the
quality of care (McCollum & Pincus, 2009). Therefore, an immune-related patient
questionnaire and referral algorithm have been developed based on the current
understanding of signs and symptoms for these AI diseases.
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According to the guidelines developed by both the American College of
Gastroenterology (Rubio-Tapia et al., 2013) and the British Society of Gastroenterology
(Ludvigsson et al., 2014), any patient with signs or symptoms of CD should undergo
testing. These include the following: chronic or recurrent diarrhea, weight loss,
abdominal pain after eating, abdominal distention or bloating after eating, history of
Irritable Bowel Syndrome (IBS), anemia, vitamin D deficiency, or elevated liver
enzymes. The aforementioned guidelines, as well as those developed by the American
Gastroenterological Association (AGA) Institute (Kagnoff, 2006), further indicate that
symptomatic, first-degree relatives with celiac disease are at a higher risk for CD than
those in the general population, with a prevalence of approximately 10%, and should be
tested for CD.
According to the American College of Gastroenterology (Lichtenstein et al.,
2009) and Laass, Roggenbuck and Conrad (2014) with the Institute of Immunology,
patients should be suspected for Crohn’s disease with the following symptomology:
chronic or recurrent diarrhea, weight loss, abdominal pain after eating, painful bowel
movements, blood in stool, or fever. The European Crohn’s and Colitis Organization
(Van Assche et al., 2009) supports testing in symptomatic patients who have previously
been told they have IBS, or have a history of anemia, vitamin D defiency, or elevated
liver enzymes. All authors agree that family history is key, due to the fact that firstdegree relatives of patients with Crohn’s disease have a 10-15 fold risk for also having
Crohn’s disease. Symptomatic patients with family history should be investigated for
Crohn’s (Laass et al., 2014; Lichtenstein et al., 2009; Van Assche et al., 2009).
Finally, recommendations from the National Guideline Clearinghouse (2012) and
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the ACR/EULAR classification criteria (Cohen & Emery, 2010) guided the questions
related to rheumatoid arthritis. Patient with the following signs and symptoms should be
considered for RA, including morning stiffing for greater than 30 minutes for more than 6
weeks, joint/muscle pain on a daily basis for more than 6 weeks, tender/swollen joints on
a daily basis for more than 6 weeks, tingling in hands/feet on daily basis for more than 6
weeks, plus weakness/fatigue for more than 6 weeks.
The purpose of this patient questionnaire is two-fold: (1) to improve and
streamline the screening process for health care providers for celiac disease, Crohn’s
disease and rheumatoid arthritis among patients with psoriasis, and (2) to elicit immunerelated information from the client that might otherwise be overlooked, decreasing the lag
time between symptom onset and diagnosis. The purpose of the referral algorithm is to
help inform provider clinical decision-making steps based on patient questionnaire
responses. As such, the DNP project author developed a patient questionnaire (See
Appendix D) and referral algorithms (See Appendices E, F and G) based on existing
evidence and guidelines for care. Neither the patient questionnaire, nor the algorithms,
has been tested for reliability or validity.
The questionnaire includes two demographic questions (age and gender), one
question regarding family history for celiac disease, Crohn’s disease, and rheumatoid
arthritis, plus sixteen primary questions, which focus on the signs and symptoms of celiac
disease, Crohn’s disease, and rheumatoid arthritis. Seven of the questions pertain to both
celiac disease and Crohn’s disease, as symptoms can be comparable between these two
AI diseases. Three questions are specific to Crohn’s disease, one specific to celiac
disease, and a total of five questions specific to rheumatoid arthritis.
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The primary questions are dichotomous, requesting a simple “yes” or “no” answer
(0 designates “no” and 1 designates “yes” for each framed question). Eight of these
primary questions are conditional; if the patient provides a “yes” response, then the
patient is directed to answer subsequent questions.
Three algorithms for referral have also been developed, one each for celiac
disease (see Appendix E), Crohn’s disease (See Appendix F), and rheumatoid arthritis
(See Appendix G). The algorithms take into consideration the patient responses to the
questionnaire and assist the provider’s clinical decision-making regarding whether or not
referral for additional specialty care and work up is merited.
3.4 Unit of analysis
The first unit of analysis is the patient questionnaire, which will be presented in
descriptive statistics (frequency tables). The second unit of analysis is the provider’s
documentation of the patient questionnaire and subsequent referral, if indicated based on
the questionnaire.
Data will be collated using a 2 x 2 table in which the two possible outcomes
include whether the patient questionnaire was administered/not administered, and
whether a referral was made/not made to a specialist for additional work-up. The
outcome evaluation will determine if the patient questionnaire has facilitated possible
identification of co-autoimmunity (celiac disease, Crohn’s disease, and/or rheumatoid
arthritis) in these psoriatic patients.
Additionally, the information provided by the patient via the patient questionnaire
will be entered in an Excel spreadsheet, one row per patient. The excel database will be
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used to calculate the prevalence of celiac disease, rheumatoid arthritis, and Crohn’s
disease symptoms among the total number (N) of psoriatic patients seen in the practice.
3.5 The Setting
The administration of the patient questionnaire will take place on location at a
private dermatology practice in Springfield, Virginia. The provider, referred to as “MD
One,” is board certified in dermatology and dermatopathology, specializing in the
diagnosis and treatment of medical, surgical and cosmetic conditions of the skin, hair and
nails. Practicing since 1973, MD One serves a racially diverse, urban population in the
greater Northern Virginia area (48.7% Caucasian, 9.0% AA, 24.3% Asian, 25.5%
Hispanic and 7.5% other). MD One accepts private insurance through Aetna, Blue Cross
Blue Shield, Cigna, as well as Medicare, but not Medicaid. The lack of current protocol
at this practice for screening patients with psoriasis for celiac disease, rheumatoid
arthritis and Crohn’s disease has created an opportunity for a quality improvement
project.
3.6 Sample
Inclusion criteria will consist of patients aged 18 years or greater, who are able to
speak, read and comprehend English, with a current diagnosis for psoriasis. Current
diagnosis for psoriasis refers to existing patients being treated by MD One for psoriasis,
as well as new referrals from primary care providers for additional psoriasis treatment.
Furthermore, self-referred patients may also be included if a new psoriasis diagnosis
occurs at the first visit with MD One. Approximately thirty patients are targeted for the
sample project.
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3.7 Description of intervention
Staff Training. The two Patient Service Representatives (PSRs) at the
dermatology practice are the initial point-of-contact for all patients and visitors.
Responsibilities include, but are not limited to, greeting patients and visitors, assisting
patients with appointment check-ins, obtaining information from new and established
patients, accurate medical record entry, scheduling appointments, and answering
telephones. The PSRs will be critical to the implementation of the quality improvement
project, as they will be responsible for identification of potential patients with psoriasis
and with dissemination of the patient questionnaire. Therefore, the author will meet with
both PSRs on the afternoon of Friday, June 9, 2017 on-site at the practice during “down”
time, after patient appointments have finished, typically around 12:30pm.
The project objective, an increased understanding of co-autoimmunity among the
psoriatic patients at the practice, as well as the supporting research, will be shared with
the PSRs in order to promote an understanding of the project and secure buy-in from
these participants. Additionally, the author will demonstrate respect for the PSRs, which
will encourage staff support. PSRs will be provided with every opportunity to voice
concern or questions over the questionnaire process. PSRs will also be asked for their
input on how to best streamline the process based on their understanding of clinic flow;
consideration will be given to their suggestions for simplifying the overall process and
this will promote ownership of project with PSRs.
Following the project introduction, the questionnaire will be reviewed, and
instruction will be given regarding the protocol for implementation of the questionnaire.
PSRs will provide the questionnaires to adult patients aged 18 and greater that have an

73

ICD-9 diagnosis code of 696 (psoriasis and similar disorders) or ICD-10 diagnosis code
of L40.0-L40.5 from a previous clinic visit at their check-in. This information will be
determined from the practice’s scheduling and billing software, MacPractice, at the
beginning of the day before the first appointment has arrived and reiterated during the
staff’s morning “huddle.” The MacPractice Management system allows the user to run
reports on existing patients by diagnosis code. For newly referred patients or selfreferred patients, the PSRs will review the reason for the patient’s appointment, via
scheduling software notes and intake form. If it is not apparent why the new patient
requires dermatological expertise, the patient will simply be asked why they are being
seen upon their arrival.
If the previously stated qualifications are satisfied, the PSR will retrieve a blank
questionnaire from a to-be-determined storage area, and give to the patient to fill out in
the lobby prior to their appointment. The PSR will collect the completed form from the
patient and paper clip, content-side down, to the front of the patient’s chart for MD One
to review prior to their appointment.
MD One Training. MD One’s buy-in is critical to the success of project
implementation. As the principal provider, the project intervention could potentially fail
without his ongoing support for the duration of this project. Therefore, MD One and the
author project will meet Friday, June 9, 2017 in order to discuss overall project
objectives, the foundations on which the project is based, and MD One’s involvement.
Research findings that support the co-existence of psoriasis and celiac disease,
rheumatoid arthritis, and Crohn’s disease will be presented to MD One. The information
will be presented in the form of a bulleted handout during a face-to-face meeting,
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providing MD One with the opportunity to ask questions and address any questions or
concerns. Additionally, the patient questionnaire and referral algorithms will be
reviewed to ensure understanding of which symptoms will prompt additional referral
needs. A project outline will also be provided defining milestones and responsibilities,
project implementation, and project completion.
First and foremost, MD One’s primary responsibility is to review the completed
patient questionnaire, noting pertinent positives. It is important to note that this
questionnaire has been designed to be simple and quick to fill-out by the patient,
highlight potential co-autoimmune burdens, and facilitate conversation; however, it is not
exhaustive, nor a replacement for additional medical history, physical exam, or testing.
Therefore, when key indicators suggest potential symptomology for celiac disease,
rheumatoid arthritis and/or Crohn’s disease, MD One will also review the referral
algorithms to determine if the patient is a candidate for referral to a gastroenterologist or
rheumatologist. If the patient meets the criteria for referral, MD One will ask the PSR to
coordinate the referral.
Although scheduling and billing for this practice are electronic, MD One uses
paper charting to document patient history, systems review, assessment and treatment
plans. For the purposes of this quality improvement project, MD One will also document
in the paper chart that the patient has been screened via patient questionnaire and if
referral was coordinated. The screening questionnaire will remain in the medical chart,
becoming a part of the patient’s permanent record. Post visit, MD One will place the
patient chart in a discharge bin for filing by the end of the day.
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Project Implementation. The implementation of the patient questionnaire will
span a total of two weeks, five workdays per week, Monday through Friday. The ideal
timeframe for project execution is June 12, 2017 through June 23, 2017.
Chart Review. The project author will review all charts placed in the discharge
bin throughout the day on a daily basis, so as not to disrupt the office’s daily rhythm and
current practices. Each chart reviewed will be recorded first, on the “Coded Identifier
List” form (See Appendix H) and second, on the “Chart Review Data Collection Form”
(See Appendix I). The author will also transcribe data from completed screening
questionnaires to the “Screening Questionnaire Data Collection Form” (See Appendix J).
Table 3.1 indicates the timeframe for project implementation and the data collection
process.
Table 3.1 Time Intervals for Quality Improvement Project
Activity

Timeframe

Obtain IRB approval

June 6, 2017 (See Appendix L)

MD One Training
Patient Service Representatives Training

June 9, 2017

Implement Patient Questionnaire
Data Collection and Retrieval

June 12, 2017 through June 23, 2017
On a daily basis during the two weeks
of project implementation

3.8 Data Management and Analysis Methods
As previously mentioned, three forms will be completed during the chart review:
the coded identifier list, the chart review collection form, and the screening questionnaire
collection form. This data will be input into an encrypted and also password-protected
excel file, which will be stored on a password-protected laptop, known only by the
author.
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The objective of the coded identifier list is to create a simple log, which will
provide a method for a) tracking charts reviewed, ensuring that there is no duplication of
data, and b) de-identifying participants through the assignment of a subject ID number,
which will then be used in the two data collection forms. The columns included in this
form are patient name, chart number, visit date, and subject ID number. The subject ID
numbers will begin with “1” and run consecutively in ascending order. This subject
number will be transferred to the chart review collection form, and as appropriate the
screening questionnaire collection form. No patient identifiers will be collected that can
be traced back to the patients’ charts.
The chart review collection form will record the subject ID number, and if the
patient has psoriasis (yes/no). If the patient was not being seen for psoriasis management
or does not have a history of psoriasis, the chart review will be completed on that patient.
If the patient does fulfill the psoriasis requirements, than the following components will
also be reviewed: if the questionnaire was completed (yes/no), if the provider
documented the screening (yes/no), and if referral was made (yes/no).
Finally, the screening questionnaire data collection form will document the
patient responses to each question for completed questionnaires. The collection form
includes the subject ID number, forty columns that correspond to both the primary and
conditional questions asked by the screening form, plus a final column that indicates
whether this patient was referred or not.
In order to organize, sort and synthesize the answers provided by the patients,
each response option has been numerically coded. The codes for each question may be
reviewed in the data collection form (See Appendix J). The initial row of this form is
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considered to be the master key for processing the data collected. A separate index
(Appendix K) has been created for the three questions on the form (13b, 14a and 15a)
uniquely pertaining to the Rheumatoid Arthritis diagram, with fifty-five designated
options denoting left, right and/or bilateral anatomical body locations.
After the data has been compiled, the author, in collaboration with a statistician,
will prepare the collected data for analysis. Data collected from the chart review will be
categorically analyzed using either the chi square or Fisher’s Exact test via SAS 9.4
statistical software. The chi square test is designed to provide marginal frequencies with
information gathered from sources with two possible outcomes. Should cells frequencies
have expected values of less than 5, Fisher’s Exact test will be used to improve analytical
accuracy.
The data will be collated using a 2 x 2 table in which the two possible outcomes
include whether the patient was screened/not screened by the provider, and whether a
referral was made/not made to a specialist. For this test, the alpha level of significance is
0.05 (α = 0.05), and the degrees of freedom equals 1 (df = 1).
The data collected from the patient questionnaire will be analyzed using Excel
spreadsheet tools. Descriptive statistics regarding the sample, as well as the prevalence
(percentages) of symptoms relating to celiac disease, Crohn’s disease, and rheumatoid
arthritis for these patients with psoriasis, will be calculated.
3.9 Human Subjects
Institutional Review Board (IRB) approval will be sought from the University of
South Carolina as an exempt study for quality improvement. Upon approval, this author
will initiate project implementation, and be exclusively responsible for data collection
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and management. Three layers of protection will safeguard all data collected in order to
ensure patient confidentiality. All data collected during the creation of the coded
identifier list, chart review data collection, and the screening questionnaire response
collection will be migrated into three separate, encrypted and also password-protected
excel files. The files will then be stored on a password-protected laptop; the master
coded identifier list will be stored separately from the collection forms data, on a second
password-protected laptop.
Data collection will occur throughout the lifespan of this quality improvement
project, during the anticipated two-week project period, on a daily basis. The author alone
will be responsible for chart reviews and data collection, which will occur in a private
office on location at the clinic. The author will retrieve completed patient charts from the
discharge bin, and relocate to the reserved office area for chart review and data
transcription. Upon completion of chart review and data transcription, the author will
return the charts to a newly designated bin, which will signal to staff that the chart is now
ready for filing. At no time will charts be left alone in the private office.
Following data collection, but prior to data analysis, the identifier code list file
will be destroyed via the free, downloadable Eraser software application (Eraser, 2016).
Initiation of the Eraser program, a security tool for Windows platforms, will guarantee
that the code list file has been permanently removed from the operating system. Subject
number alone will ultimately catalogue and ensure non-duplication of patient data; no
patient data or responses will be linkable to patient identities.
The data collected for this quality assurance project will focus solely on whether
the provider screened the psoriatic patient, if the patient was referred for additional
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specialty evaluation as a result, and the patients’ answers from the screening
questionnaire. The descriptive statistics produced from the questionnaire will reflect the
cohort in the aggregate. Finally, this project will practice patient respect throughout;
patients have the right to refuse to participate in patient screening, no questions asked.
3.10 Framework/model of research
The Iowa model of evidence-based practice to promote quality care was very
influential throughout the development of this practice-change project (Melnyk &
Fineout-Overholt, 2011). This model provides a step-by-step framework for nurse
research utilization toward improving patient care. The model’s first step was utilized to
define an opportunity for improvement regarding knowledge about psoriasis and coautoimmunity with celiac disease, rheumatoid arthritis and Crohn’s disease. The
culmination of this step resulted in the PICO question. The second and third steps in the
Iowa model guided the evidence search and then, the critical appraisal of the literature
included in this systematic review, ensuring the integrity and quality of the data collected.
The fourth step directed the practice change design process through the identification of
proposed practice change, identifying resources, evaluation design development and plan
implementation (Melnyk & Fineout-Overholt, 2011). The final two steps, five and six,
influence the implementation of the pilot study and integration of study into standards of
practice. Step five outlines the critical steps for implementing the quality assurance
project to include an evaluation of process, outcomes, costs and the development of
conclusions and recommendations (Melnyk & Fineout-Overholt, 2011). Step six of the
model discusses how to integrate and maintain change in practice, through the process of
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engaging stakeholders, incorporating the change into the practice, monitoring the process,
and distribution of final outcomes (Melnyk & Fineout-Overholt, 2011).
3.11 Strategies to reduce barriers and increase supports
To reduce potential barriers, such as provider or staff resistance to the
implementation of a practice change, meetings with key change champion and opinion
leader, MD One, and central staff players (PSRs) will be arranged. MD One’s and staff
buy-in is critical to the process of project implementation. It is critical that MD One and
staff appreciate the value of an increased understanding of their patient population toward
promoting improved patient outcomes for patients with psoriasis. At the meetings with
MD One and staff, the need for change in practice, as well as the compelling evidence
that supports this need for change, will be discussed. Printed materials summarizing key
points will supplement the discussion and be provided for distribution among clinic staff.
Patient resistance to participate and complete the patient questionnaire is also a
possible barrier. The patient questionnaire has been designed to take no more than five
minutes to complete, and will be provided to the patient with the other pre-appointment
documentation. The patient will be able to complete the questionnaire while waiting in
the lobby, therefore, not extending the patient’s personal time burden at the visit.
Finally, the author will be onsite for the duration of the project implementation
and immediately available for patient questions, as well as staff and MD One support, in
order to help ease the transition of a new practice change.
3.12 Summary
Additional population studies are urgently needed in order to determine the
association of psoriasis with other AI disorders, and namely with celiac disease, Crohn’s
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disease, and rheumatoid arthritis. This quality improvement project will demonstrate that
healthcare providers may have previously not been aware of co-autoimmunity in their
psoriasis patients, demonstrate the ability to determine this information with a patient
questionnaire, and foster increased awareness among healthcare providers about the
autoimmune state of their psoriatic patients.
Clinicians should consider psoriasis as a systemic inflammatory disorder with
potential for other autoimmunity issues, rather than an isolated skin disease. Increased
awareness about co-autoimmunity in the patient with psoriasis is necessary for optimal
patient management and will help to facilitate best patient outcomes.
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Chapter 4
Results
4.1 Introduction
The aim of this project was to assess the utility of early screening in patients with
psoriasis in order to facilitate earlier diagnosis of CD, RA and CrD, which would
consequently initiate earlier treatment and improve long-term patient outcomes. The
outcomes measured include the responses from the patient questionnaire and if the
provider documented screening for polyautoimmunity and referral indications. Chapter
four provides a summary of these results from the quality improvement project and is
divided into the following sections: description of the sample, analysis of the research
questions, and conclusion.
The analysis is divided into four sub-sections. The first sub-section focuses on
the answers to the primary questions that directly fed the algorithms. The second subsection discusses the answers to the conditional questions, which collected additional
information on symptoms. The third sub-section discusses the retrospective chart review,
and the last sub-section examines more closely the patients who fulfilled the requirements
for additional evaluation for celiac disease, Crohn’s disease and rheumatoid arthritis
based on their reported symptoms.
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4.2 Description of Sample
This quality improvement project occurred during the weeks of June 12, 2017
through June 23, 2017, covering 10 business days at a Northern Virginia dermatology
clinic. A total of # (n=261) were seen at the clinic for a variety of different skin
disorders. Thirty-four adult patients with either a history of psoriasis or a new diagnosis
of psoriasis completed the patient questionnaire during this timeframe, which assessed for
the presence of evidence-based signs and symptoms for celiac disease, Crohn’s disease
and rheumatoid arthritis. Seventeen of these patients (50%) were female; seventeen
(50%) were male. The mean age of the psoriatic patients was 55.71 years old, ranging in
ages 18 to 81 years old.
4.3 Analysis of Research Questions
Two unit of analysis were identified for this quality improvement project. The
first unit of analysis was the patient questionnaire. The second unit of analysis was the
provider’s documentation of the patient questionnaire and subsequent referral, if
indicated based on the questionnaire. Six tables are presented below to review the data
collected from this quality improvement project.
Patient Questionnaire: Primary Questions. Table 4.1 depicts the participants’
responses to the seventeen primary questions from the patient questionnaire. Frequency
data indicated that the most reported symptom was a history of vitamin D deficiency
(38.24%). Thirty percent of psoriatic patients reported having a first-degree relative with
celiac disease, Crohn’s disease or rheumatoid arthritis. The next most frequently reported
symptoms were for rheumatoid arthritis: daily joint or muscle pain > 6 weeks (29.41%),
daily tender or swollen joints > 6 weeks (23.53%), and weakness or fatigue > 6 weeks
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(23.53%). The most reported GI symptom was abdominal distention and/or bloating after
eating (14.71%). The least reported symptoms, at 2.94% each, were abdominal pain after
eating, painful bowel movements, and running a fever in the past 4 weeks (Table 4.1).
Table 4.1 Patient Questionnaire Frequency Distributions / Primary Questions
Question #
11

1

14

15

17

13

16

5

Question
Has a HCP ever
told you that you
have a Vitamin
D deficiency?
Do you have a
1st degree
relative with
CD, CrD or RA?
Have you had
joint or muscle
pain on a daily
basis for > 6
weeks?
Have you had
any tender or
swollen joints on
a daily basis for
> 6 weeks?
Have you had
weakness or
fatigue for > 6
weeks?
Have you had
morning
stiffness in any
of your joints for
> 60 minutes for
> 6 weeks?
Have you had
tingling
sensations in
your hands or
feet on a daily
basis for > 6
weeks?
Do you suffer
from abdominal
distention and/or
bloating after

Yes

No

N
13

%
38.24

N
21

%
61.76

10

29.41

24

70.59

10

29.41

24

70.59

8

23.53

26

76.47

8

23.53

26

76.47

6

17.65

28

82.35

6

17.65

28

82.35

5

14.71

29

85.29

85

7
12

2

3
9
10
4
6
8

eating?
Have you ever
seen blood in
your stool?
Has a HCP ever
told you that you
have elevated
liver enzymes?
Do you have
chronic or
recurrent
diarrhea (≥ 3
loose stools per
day for > 4
weeks)?
Have you been
losing weight?
Has a HCP ever
told you that you
have IBS?
Has a HCP ever
told you that you
were anemic?
Do you have
abdominal pain
after eating?
Is it painful to
have a bowel
movement?
Have you had a
fever in the past
4 weeks?

5

14.71

29

85.29

4

11.76

30

88.24

2

5.88

32

94.12

2

5.88

32

94.12

2

5.88

32

94.12

2

5.88

32

94.12

1

2.94

33

97.06

1

2.94

33

97.06

1

2.94

33

97.06

Patient Questionnaire: Frequency Distributions / Conditional Questions.
Tables 4.2, 4.3 and 4.4 depict the responses for the nine conditional questions
asked by the patient questionnaire. If a patient answered “yes” to any of the nine
conditional questions, they were then prompted to answer additional questions. The
additional questions were developed in order to collect supplementary information related
to the patient’s initial positive response. These responses are also presented by
frequency. The primary questions are shaded in grey, by row, and the related conditional
responses are indented just below, a summary of which follows.
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For the 29.41% psoriatic patients that reported having a first-degree relative with
CD, CrD or RA, 46.51% of individuals reported that this relative was their mother. CD
was reported in 38.46% of the cases, with CrD and RA each being reported in 30.76% of
the cases of first-degree relative. One individual had a mother with both CD and RA; a
second individual reported having a child with both CD and CrD, and a third individual
reported having a mother with CD and a brother with CrD.
Joint and muscle pain for greater than six weeks was reported by 29.41% of
psoriatic patients. Tender and swollen joints on a daily basis for greater than six weeks
was reported by 23.53%. 17.65% reported morning stiffness in their joints for more than
60 minutes a day for greater than six weeks. Although responses varied per patient,
collectively these individuals indicated that their pain, tenderness, swelling and stiffness
was located either bilaterally, or unilaterally, at the neck, shoulders, hands, fingers, hips,
knees, ankles, and feet. Sixty percent of these respondents indicated that their pain was
between a 5-7 on a pain scale of 0 (no pain) to 10 (worst pain of their life). 50% reported
a “constant” pain, and 40% described their pain as “aching.” Fifty percent of the patients
that indicated morning stiffness said that they experienced it everyday.
Weakness or fatigue for greater than 6 weeks was reported in 23.53% of psoriatic
patients, and 55.56% indicated that they experienced their weakness and fatigue 1-3 days
per week. Two patients (5.88%) reported weight loss over the past 6 months. One
individual reported a loss of 15-pounds and the other reported a 20-pound loss. Only one
patient (2.94%) reported abdominal pain after eating, in the LUQ, causing 3/10 cramping
pain that lasted for one hour. Finally, one patient (2.94%) reported having a fever of
101°C in the past 4 weeks.
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Table 4.2 Questionnaire Frequency Distributions / First Degree Relative
Question #
1

Primary
Question
Do you
have a 1st
degree
relative
with CD,
CrD or
RA?

Conditional
Question

Conditional
Response

Do you have a
mother/father/sister/
brother/child with …

Mother
Father
Sister
Brother
Child
CD
CrD
RA

… CD, CrD or RA?

N

%

10 patients
reported one or
more 1st degree
relative(s) with
CD, CrD and/or
RA.

29.41

6
2
1
1
3
5
4
4

46.15
15.38
7.69
7.69
23.07
38.46
30.76
30.76

Table 4.3 Questionnaire Frequency Distributions / Conditional GI symptoms
Question #
3

Primary
Question
Have you
been
losing
weight?

Conditional
Question

Conditional
Response

How much weight have
you lost over the past 6
months?
4

%

2 patients reported
losing weight.

5.88

1
1

50
50

1 patient reported
abdominal pain

2.94

LUQ

1

100

3/10

1

100

1 hour

1

100

Cramping

1

100

1 patient reported
having a fever

2.94

15 pounds
20 pounds

Do you
have
abdomin
al pain
after
eating?
Where does your pain
occur?
How would you rate your
pain?
How long does the pain
last?
How would you describe
the pain?

8

N

Have you
had a
fever in
the past 4
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weeks?
What was your
temperature?

fever=101°
C

1

100

Table 4.4 Questionnaire Frequency Distributions / Conditional Arthritis Symptoms
Question #
14

Primary
Question
Have you
had joint
or muscle
pain on a
daily
basis for
>6
weeks?

Conditional Question / Response

N

%

10 patients
reported joint or
muscle pain

29.41

1
1

10
10

1

10

1

10

1
1

10
10

1

10

1
1
1

10
10
10

1
1
1
2
2
2
1
1

10
10
10
20
20
20
10
10

5
1

50
10

1

10

Where is your pain located?
• bilateral knees
• bilateral neck, bilateral shoulders,
bilateral hips
• bilateral neck, right shoulder, left knee,
left ankle
• bilateral pointer fingers, bilateral
middle fingers, bilateral ring fingers,
bilateral pinky fingers
• left hand, left ankle, right foot
• left hip, left knee
• left shoulder, bilateral hands, bilateral
hips, bilateral feet
• left shoulder, left hand
• left shoulder, left hip, left knee
• right neck
How would you rate your
pain?

How long does the pain
last?
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1/10
3/10
4/10
5/10
6/10
7/10
9/10
2-6 hrs to
constant
constant
comes and
goes
depends on
site

How would you describe
the pain?

15

hours
morning
throbbing
shooting
stabbing
cramping
aching
pressure
cramping
burning
aching
asleep

Have you
had any
tender or
swollen
joints on
a daily
basis for
>6
weeks?

1
1
1
1
2
1
4
1
1
3
2
1
8 patients reported
tender or swollen
joints

10
10
10
10
20
10
40
10
10
30
20
10
23.53

1
1
2

25
12.5
25

1

12.5

1
1

12.5
12.5

1

12.5

8 patients reported
weakness/fatigue

23.53

3
5

33.33
55.56

1

11.11

6 patients reported

17.65

Which joints have been tender or
swollen?
• bilateral ankles
• bilateral neck, bilateral shoulders
• bilateral pointer fingers, bilateral
middle fingers, bilateral ring fingers,
bilateral pinky fingers
• bilateral pointer fingers, bilateral
middle fingers, bilateral ring fingers,
bilateral pinky fingers, bilateral ankles,
bilateral feet
• right ankle, left foot
• right knee
• right pointer finger, right middle
finger, right ring finger, right pinky
finger
17

Have you
had
weakness
or fatigue
for > 6
weeks?
How often do you have
weakness or fatigue?

13

Every day
1-3
days/week
4-6
days/week

Have you
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had
morning
stiffness
in any of
your
joints for
> 60
minutes
for > 6
weeks?

joint stiffness

How often do you have
morning stiffness > 60
minutes?

Every day
1-2 days/
wk
4-6 days/wk

3
2

50
33.33

1

16.67

• bilateral hands, left knee
• bilateral neck, bilateral shoulders,
bilateral hips
• bilateral neck, bilateral shoulders, right
wrist, bilateral pointer finger, bilateral
middle fingers, bilateral ring fingers,
bilateral pinky fingers, right hip,
bilateral feet
• bilateral pointer finger, bilateral
middle finger, bilateral ring finger,
bilateral pinky finger
• left hand, left ankle, right foot
• left pointer finger, left middle finger,
left ring finger, left pinky finger

1
1

16.66
16.66

1

16.66

1

16.66

1

16.66

1

16.66

Which joints are stiff?

Chart Review. Table 4.5 depicts the data collected during the chart review. A
total of 261 patient charts were reviewed. For 227 of the charts, the review was
completed and closed when the DNP project investigator determined that the patient did
not have a history of, or a new diagnosis for, psoriasis. The remaining 34 patient charts
demonstrated either a history of, or a new diagnosis for, psoriasis. Provider
documentation for all 34 patients demonstrated 100% compliance for noting that the
patient a) had been screened, and b) if referral was or was not indicated.
During the project-planning phase that was summarized in chapter 3, the author
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initially had intended on categorically analyzing the chart review data with a chi square
test or Fisher’s Exact test. The purpose of this analysis was to provide marginal
frequencies with information gathered from sources with two possible outcomes. Since
100% compliance occurred, neither the chi square nor Fisher’s Exact test could be
utilized. On the recommendation of the collaborating statistician, no alternative tests
were appropriate for further analyzing this data.
Table 4.5 Chart Review
Total
Sample
(n)
261

Pts with
psoriasis
N
34

Patients
Screened
N
34

Documentation of
screening
N
%
34
100

%
100

Documentation of
referral (y/n)
N
%
34
100

Referred Patient Symptoms. Table 4.6 depicts the signs and symptoms for the
eleven patients who were referred for additional evaluation based on their patient
questionnaire responses. Prior to discussing these results, a brief recap is provided first
of the evidence-based algorithms for referral care. CD should be considered in any
patient with a first-degree relative with CD and who also demonstrates any of the targeted
GI symptoms. Without a first-degree relative, CD should be considered if the patient has
three or more of the GI symptoms (See Appendix E). CrD evaluation is indicated for
patients who have a first-degree relative with CrD and who demonstrate any of the GI
symptoms acknowledged to occur with CrD. If the patient does not have a first-degree
relative, they may be considered if they have had chronic diarrhea for more than 4 weeks
and have at least one of the identified GI symptoms (See Appendix F). Finally, patients
should be considered for RA if they have synovitis in at least one joint or three or more
arthralgia symptoms (See Appendix G).
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As per the chart review, the responses provided by 11 of the 34 psoriatic patients
indicated that they should receive additional evaluation by either a gastroenterologist or a
rheumatologist. Upon development of Table 4.6, however, the author realized that two of
the patients (subjects 8 and 23) did not actually satisfy the algorithm requirements. This
indicates that an element of user-error compromised the process when evaluating the
completed questionnaires.
The remaining nine patients (26.47%) did, in fact, satisfy the algorithms. Based
on the patient questionnaire responses, five individuals fulfilled the requirements for
additional celiac disease evaluation and six individuals fulfilled the requirements for
additional rheumatoid arthritis evaluation. Two of the nine patients merited additional
evaluation for both celiac disease and rheumatoid arthritis. No patients were referred for
possible Crohn’s disease. In the table below, for each of the subjects a red “X” depicts
the patient’s reported GI symptoms, while a blue “X” depicts reported arthritis
symptoms.

X

X

X

X

X

X
X

X

X

X

X

X

Eval
X

X
X

Weakness

X

Tingling

Pain Joint

X

Swelling

Stiffness

Hx LFTs

M

Hx Vit D Def.

68

Hx Anemia

M

Hx IBS

46

Fever

M

Blood in stool

23

X

Painful BM

M

Abd distention

12

X

Abd Pain

M

Weight Loss

11

4
0
4
9
5
7
5
0
6
4
4

Diarrhea

F

Relative

Gender

8

Age

ID#

Table 4.6 Patient Symptoms Warranting Additional Evaluation

X
X
X
X

X
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X

X

X

X

X

X

13
3
13
9
19
4
22
1
23
0

F
F
M
M
F

1
4
8
5
9
5
7
4
3
7
5

X

X

X
X

X

X

X

X

X

X

X

X

X

X
X

X

X

X

X

X

X

X

X

X

X

X

X
X

X

X

X

X
X

GI Symptoms = X; arthritis symptoms =X
4.4 Conclusion
This quality improvement project highlights several important facts. First, with
proper planning, time commitment and a champion for change, real process
modifications in health care management are possible. By utilizing and implementing the
steps provided by the Iowa Model for Evidence Based Practice, the foundation for change
was established for successful screening of adult patients with psoriasis for celiac disease,
Crohn’s disease, and rheumatoid arthritis. Of the 34 patients identified with a diagnosis
for psoriasis, all were appropriately screened for polyautoimmunity. Provider
documentation demonstrated buy-in and compliance with this project.
Although two patients were inappropriately flagged for additional evaluation, this
provides an opportunity to re-evaluate the patient questionnaire review step. This DNP
Project investigator theorizes that the responses to the conditional questions, whose
answers are not applied against the algorithms, but were meant for collecting additional
symptom history, may have complicated the questionnaire review. With this in mind,
three possible methods for improving this step have been identified.
The simplest option would be to have a PSR pre-screen the questionnaire and
indicate via highlighter marker only the positive answers to primary questions before
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provider review. Further, an algorithm check-box could be developed and completed for
each questionnaire. This would provide an alternative and more concise view of
responses as they relate to the algorithms. Unfortunately, with both of these alternatives,
an opportunity for human-error still exists. The most sophisticated option includes the
development of a computer-based questionnaire that would have built in rules for
analyzing the data and automatically determining whether a referral is indicated.
Obviously, this would require additional cost for software development and hardware
(tablets or laptops for patient use), but would effectively eliminate user-error.
The second significant take-away from this quality improvement project is that a
real need exists for evaluating adult patients with psoriasis for polyautoimmunity and
familial autoimmunity. The fact that nine of the 34 patients, or 26.47% of psoriatic
patients indicated for further evaluation based on their reported gastrointestinal and/or
arthritic symptoms underscores that need for provider screening and is consistent with the
literature. Additionally, 29.41% of the psoriatic patients reported having a first-degree
relative with CD, CrD and/or RA (8.82% of whom merited additional evaluation)
supports the literature that states providers should be asking about their family history of
autoimmune disorders.
Despite having flagged nine patients with psoriasis for referrals, it is important to
note that an indication for referral does not automatically indicate a diagnosis for coautoimmunity. Additional evaluation is necessary in order to rule-out the many other
possible differential diagnoses that could be associated with these symptoms. The bestcase scenario as it relates to this quality improvement project is that these individuals
with psoriasis may be identified as having celiac disease, Crohn’s disease or rheumatoid
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arthritis earlier in the course of their disease, improving long-term patient outcomes.
Worst-case scenario is that these patients are evaluated for these symptoms that need
additional evaluation anyway.
Despite this limitation, this quality improvement project demonstrates the
merging of two relatively distinct evidence-based practices and research: 1) the current
practice for evaluating patients for celiac disease, Crohn’s disease and rheumatoid
arthritis and 2) the literature that suggests that these practices should be proactively
applied to patients with psoriasis.
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Chapter 5
Discussion
5.1 Introduction
The purpose of this project was to conduct a substantive review of the literature to
determine if screening primary care patients with psoriasis will improve early detection
of celiac disease, rheumatoid arthritis, and Crohn’s disease. The aim of this project was
to assess the utility of early screening in patients with psoriasis in order to facilitate
earlier diagnosis of CD, RA and CrD, which would consequently initiate earlier treatment
and improve long-term patient outcomes. The evidence-based practice question is: In
adult patients aged 18 years and greater with psoriasis, does screening for celiac disease,
rheumatoid arthritis, and crohn’s disease improve early detection for these autoimmune
disorders? A retrospective chart audit of 261 adult patients with psoriasis was conducted
for polyautoimmunity screening. Chapter five presents recommendations and
implications for practice, education, research and policy development.
5.2 Recommendations for Practice
According to the quality improvement project and consistent with the literature,
there is evidence supporting prospective evaluation of adult patients with psoriasis for
polyautoimmunity, specifically celiac disease, Crohn’s disease and rheumatoid arthritis.
Findings from the project underscore the need for provider utilization of a patient
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questionnaire that promotes identification of family history of autoimmune disorders, as
well as significant symptoms for each of these three autoimmune disorders in the patient
with psoriasis. Further, the adoption of a screening process for polyautoimmunity in
psoriatic patients in outpatient settings would help to narrow the provider’s focus on
polyautoimmunity. This is as opposed to managing symptoms without respect for the
relationship among autoimmune diseases, missing the potential connection, and allowing
AI disease to progress unchecked.
5.3 Recommendations for Education
Improved clinical awareness among health care providers about the coexistence of
AI diseases within individuals may also play a critical role in providing the best patient
care and in achieving the best patient outcomes. Health care practitioners must
acknowledge that the presence of one AI disease may be indicative for the potential of
other AI diseases. Dermatologists and primary care providers in particular, as the usual
gatekeepers for diagnosis and management of psoriasis, should been keenly aware of the
possibility of other, latent AI disease in the adult patient with psoriasis.
Ideally, this improved awareness should start in the classroom. The educational
institution’s commitment to producing the best future health care providers should
include foundational instruction regarding autoimmune disorders as a disease continuum
worthy of its own category, and not simply as part of the current and traditional disease
classification by organ system.
Educating providers about prospective evaluation of polyautoimmunity in patients
with psoriasis must include discussions on the background and significance of the most
current genetic and population-based studies that tie psoriasis, celiac disease, Crohn’s
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disease and rheumatoid arthritis to each other. Research publications continue to be the
best method for reaching the most providers in the field.
5.4 Recommendations for Research
Additional research and improved awareness of autoimmune disorders, among
both the public and healthcare providers, remains the cornerstone of future efforts to
better understand autoimmune disorders, to better understand their co-existence, and
toward a better plan for diagnosis and management of AI disorders. Despite research
advances made in the past two decades, substantial deficits remain in the understanding
of psoriasis, the most commonly diagnosed AI disorder in the United States.
Specifically, a greater understanding of the pathogenesis of psoriasis, comorbidities, and
patient treatment demands further research in these areas. However, psoriasis research
should not be conducted within a vacuum. While it is critical to understand how psoriasis
stands alone as an autoimmune disorder, it is also imperative to develop research toward
understanding how and why psoriasis co-exists with other autoimmune disorders. For
example, why is there a 2.3-fold greater risk of celiac disease co-occurring with psoriasis
(Wu et al., 2013)? And compared to individuals without psoriasis, why do subjects with
psoriasis have a 3.02-fold increased risk of rheumatoid arthritis (Tsai et al., 2011)? Aside
from seeking answers to these questions about psoriasis and its co-existence with other
AI disorders, there also exist other compelling reasons for targeting psoriasis in
autoimmune research.
First, psoriasis is known to be the most prevalent AI disorder in the United States,
affecting as many as 7.5 million Americans, and 125 million worldwide (National
Psoriasis Foundation, 2014). Second, the concept of pan autoimmunity, or diathesis of
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autoimmunity (Ali & Warren, 2013; Pender et al., 2002), proposes that individuals with
one autoimmune disease are predisposed genetically to other autoimmune diseases.
Extrapolating the pan autoimmunity theorem to apply to patients with psoriasis, we can
therefore expect that these individuals would also be genetically predisposed to other
autoimmune diseases. However, this supposition is not just a leap of blind faith;
epidemiological data already supports this hypothesis. The literature reviewed for this
project strongly suggests a link between psoriasis and celiac disease, rheumatoid arthritis
and Crohn’s disease (Augustin et al., 2010; Bhatia et al., 2014; Birkenfeld et al., 2009;
Cohen et al., 2009; Damasiewicz-Bodzek & Wielkoszynski, 2008; Einarsdottir et al.,
2009; Li et al., 2013; Makredes et al., 2009; Qui et al., 2013; Radtke et al., 2015; Tsai et
al., 2011; Tsoi et al., 2013; Wolf et al., 2008; Wu et al., 2012).
Therefore, given the sheer number of individuals available for basing research
inquiries, plus the existing data suggesting AI co-existence patterns, individuals with
psoriasis would seem to be a highly relevant patient population by which to start building
on our current understanding of polyautoimmunity. The research community must,
therefore, pay greater attention to the underlying genetic relationships between psoriasis
and other autoimmune disease, and to how this genetic relationship influences the
individual and familial clustering of many inflammatory and metabolic disease processes.
Another challenge to the field of immunology that demands attention is the
development of reproducible, cost-efficient, and sensitive tools for early and definitive
diagnosis, disease staging, and identification of at-risk individuals (NIH, 2005).
Fortunately, many research initiatives are currently underway and increased NIH research
funding for autoimmune diseases has trended upward from $587 million in 2007 to $821
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million in 2013 (AARDA, 2011). And in 2009, the Centers for Disease Control and
Prevention (CDC) led an effort to develop the first-ever public health agenda for psoriasis
and psoriatic arthritis, which will guide future public health efforts and research into
these diseases. Congress approved $1.5 million to the CDC to begin the first federal
effort to collect data on people with psoriatic diseases (CDC, 2010).
Among the many initiatives currently in place are the Multiple Autoimmune
Diseases Genetics Consortium (MADGC), Environment/Infection/Gene Interactions in
Autoimmune Diseases, Autoimmunity Centers of Excellence, Autoimmune Biomarkers
Collaborative Network, Cooperative Study Group for Autoimmune Diseases Prevention
(Prevention Centers), Autoimmunity Centers of Excellence, and Clinical Trials and
Clinical Markers in Immunologic Diseases (AARDA, 2011). Each of these initiatives’
overall objective, while unique, is to facilitate autoimmunity research collaboration, to
identify and characterize the genes that are common to these diseases, to develop biologic
markers for measuring disease activity, risk, and therapeutic effect, and to advance our
understanding of treatment interventions (AARDA, 2011).
5.5 Recommendations for Policy
The challenges, and solutions, to the autoimmune problem are wide-ranging and
complex. As the work continues in solving the autoimmunity puzzle, the immediate need
is for increased awareness among patients and healthcare providers about the immensity
of this public health concern and for Congress to recognize autoimmunity’s overall
financial burden to the nation. The challenges of autoimmunity need to be recognized as
a high priority agenda item today.
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5.6 Limitations
This quality improvement project capitalizes on the most current research and
evidence-based literature, however, there are many limitations to this project that must be
acknowledged. A prominent limitation of this project is that the patient questionnaire and
algorithms’ ability to adequately assist with the identification of celiac disease, Crohn’s
disease and rheumatoid arthritis have not been investigated; neither the questionnaire, nor
the algorithms have been tested for reliability or validity. Fortunately, it was never
intended for this questionnaire to be a replacement for additional medical history,
physical exam, or testing. The objective was to assist the provider in identifying potential
signs and symptoms for other AI disease in an at risk patient population, adult patients
with psoriasis.
Other limitations include location, sample size, and length of study. While a
dermatology clinic lends itself perfectly to this quality improvement project in terms of
patient population, a limitation is that the patient must then be referred out for additional
evaluation, if suspicion is high for other disease. The dermatologist in this case, and most
likely in other dermatology clinics, will not be willing to conduct further studies prior to
the specialty referral. While this is considered to be a disadvantage in the dermatology
clinic, it would actually be an advantage in the primary care practice setting. Additional
testing could be conducted in the primary care setting before deciding if specialty referral
was merited.
Finally, the sample size for this quality improvement project was relatively small
(n = 34) and all patient participants were from an urban part of the state of Virginia. The
length of time for the project was a significant limitation to this study, allotting for only
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two weeks to implement the patient questionnaire. Due to the short lifespan of the
project, the author does not know the result of any of the patient referrals.
5.7 Conclusion
While many of the AI diseases have low prevalence as a single occurring health
disease, collectively autoimmune diseases are the third most common category of disease
in the United States after cancer and heart disease (NIH, 2005) affecting approximately 58% of the population or approximately 23.5 million Americans. Psoriasis is known to be
the most prevalent AI disease in humans (Raychaudhuri, 2014), affecting approximately
2-5% of the world population and as many as 7.5 million Americans (NIH, 2005). The
concept of pan autoimmunity, or diathesis of autoimmunity (Ali & Warren, 2013; Pender
et al., 2002), proposes that individuals with one autoimmune disease are predisposed
genetically to other autoimmune diseases. Finally, the literature suggests that there is a
genetic link between psoriasis, celiac disease, Crohn’s disease and rheumatoid arthritis
(Augustin et al., 2010; Bhatia et al., 2014; Birkenfeld et al., 2009; Cohen et al., 2009;
Damasiewicz-Bodzek & Wielkoszynski, 2008; Einarsdottir et al., 2009; Li et al., 2013;
Makredes et al., 2009; Qui et al., 2013; Radtke et al., 2015; Tsai et al., 2011; Tsoi et al.,
2013; Wolf et al., 2008; Wu et al., 2012).
In light of these statistics, as providers, researchers, educators and policy makers,
we must recognize the two following realities: 1) the significance of familial
autoimmunity and polyautoimmunity to the adult patient with psoriasis, and 2) the
possibility of encountering many undiagnosed and subclinical cases of “other”
autoimmune disease in the psoriatic patient population. By acknowledging these
autoimmune principles, the provider is able to then act proactively for the patient and
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routinely consider the possibility that a patient with psoriasis may develop celiac disease,
Crohn’s disease or rheumatoid arthritis over the course of their lifetime. Providers are
able to have a lasting impact on the well-being of psoriatic patients through the
prospective evaluation of signs and symptoms of these autoimmune diseases.
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Appendix A
Scottish Intercollegiate Guidelines Network (SIGN) Grading System 1999 – 2012:
Levels of Evidence
1++ High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low
risk of bias
1+ Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias
1-

Meta-analyses, systematic reviews, or RCTs with a high risk of bias

2++ High quality systematic reviews of case control or cohort or studies
High quality case control or cohort studies with a very low risk of confounding or
bias and a high probability that the relationship is causal
2+ Well-conducted case control or cohort studies with a low risk of confounding or
bias and a moderate probability that the relationship is causal
2Case control or cohort studies with a high risk of confounding or bias and a
significant risk that the relationship is not causal
3

Non-analytic studies, e.g. case reports, case series

4

Expert opinion
(SIGN, 2013)
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Appendix B
Evidence Table
Brief Reference
1
Psoriasis
Crohn’s
Celiac
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Tsoi, L.C., Spain, S.L, Knight, J.,
Ellinghaus, E., Stuart, P.E., Capon,
F.,…Trembath, R.C. (2013).
Identification of fifteen new
psoriasis susceptibility loci
highlights the role of innate
immunity. Nature Genetics,
44(12), 1341-1348.

Type of study/
Quality rating
Meta-Analysis
Level of
evidence: 1+

Methods
A meta-analysis
of three GWAs
and two
independent
datasets
genotyped on
the “Immunochip,” to include
a total of 10,588
cases (patients
with psoriasis)
and 22,806
controls.

Threats to validity/
reliability
GWAS studies are
only able to detect
an association for a
genomic region,
and not causation of
a mutation, that
may be involved in
the development of
the disease or trait.

Findings

Conclusions

A genome-wide
significance
(P<5x10-8) for 19 of
the 21 known
psoriasis loci.
Nominal evidence
was demonstrated
for the two
remaining loci.
Fifteen new risk loci
for psoriasis were
also identified that
fulfilled genomewide significance Of
the total 39 known
and new psoriasis
susceptibility loci
included in this
study, ten of these
loci overlapped with
Crohn’s disease,
nine with celiac
disease, and five
with rheumatoid
arthritis.

Additional
genomic studies
are required to
further identify
the underlying
causal variants
with psoriasis
susceptibility
loci, leading to
increased
understanding of
pathogenic
mechanisms and
new therapeutic
targets.

2
Psoriasis
RA
Celiac

Qiu, Z.X., Zhang, K., Qiu, X.S.,
Zhou, M. & Li, W.M. (2013).
CD226 Gly307Ser association with
multiple autoimmune diseases: A
meta-analysis. Human
Immunology, 74, 249-255.

Meta-Analysis
Level of
evidence: 1+
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A meta-analysis
to evaluate the
relationship
between the
nonsynonymous
single
nucleotide
polymorphism
(SNP)
Gly307Ser
(rs763361) in
the CD226 gene
that has been
reported to be
associated with
several AI
diseases,
including
psoriasis, celiac
disease, and
rheumatoid
arthritis.
The authors
conducted a
comprehensive
search of the
U.S. National
Library of
Medicine’s
PubMed and
Embase
databases.
Seven published
studies met the

This study lacked
the original
information for the
individuals in the
included studies; as
such, data could not
be stratified by
other variables,
such as gender, and
mean age at onset
(Qui et al, 2013).
The lack of original
data also means that
the authors would
not have been able
to validate each
case for the metaanalysis. Therefore,
the possibility of
diagnoses
misclassification in
the original studies
cannot be
completely
excluded. Second,
races other than
South American,
Asian, European
and Estonian were
not represented in
this meta-analysis.
Third, the authors
note that while their
publication bias
showed no
significance, it

The evaluation of
the association of
CD226 Gly307Ser
(rs763361)
polymorphism with
multiple AI diseases
demonstrated an
overall OR 1.19
(95% CI: 1.12-1.27,
Pheterogeneity=0.136),
The authors also
conducted a
subgroup analysis
by ethnicity, where
increased risks were
found for South
Americans
(OR=1.31, 95%
CI=1.17-1.48,
Pheterogeneity =
0.644), Asians
(OR=1.23, 95%
CI=1.11-1.38,
Pheterogeneity =
0.690), and
Europeans
(OR=1.13, 95%
CI=1.04-1.24,
Pheterogeneity =
0.085) (Qui et al,
2013).
Heterogeneity
existed among both
the overall

A significantly
increased
multiple AI
disease risk was
found to be
associated with
the t allele
rs763361.

3
Psoriasis
Celiac

121

Bhatia, B.K., Millsop, J.W.,
Debbanch, M. Koo, J., Linos, E. &
Liao, W. (2014). Diet and
psoriasis, part II: Celiac disease
and role of a gluten-free diet.
Journal of the American Academy
of Dermatology, 71(2), 350-358.

Meta-Analysis
Level of
evidence: 1+

inclusion
criteria,
covering 7,876
cases and 8,558
controls. The
sample sizes
varied from 90
to 2,838 and
included two
European, two
Asian, one
South American
and three
Estonian studies.
Meta-analysis of
populationbased studies
examining the
co-occurrence of
psoriasis and
celiac disease,
investigations of
celiac disease
antibody
markers in
psoriatic
cohorts, and
clinical trials
examining the
therapeutic
benefit of a
gluten free diet
(GFD) in
patients with
psoriasis

cannot be
completely ruled
out due to exclusion
of relevant
publications that
were not indexed by
their selected
databases, PubMed
and Embase (Qui et
al, 2013).

comparison and in
sub-group analysis,
but none were
notable.

Three population
studies were
reviewed, all of
which demonstrated
that patients with
psoriasis are at an
increased risk for
celiac disease.
Fourteen studies
related to serological
celiac disease
markers in psoriasis
patients were
reviewed. Of these
fourteen, nine
studies reported a
positive association
between celiac
disease markers,
while seven did not
find statistically
significant evidence

health care
providers should
screen their
patients with
psoriasis for
symptoms of
celiac disease,
including
diarrhea,
flatulence,
fatigue and
history of irondeficiency
anemia. Positive
findings should
flag providers to
then run
serological tests
for celiac
associated
antibodies

for an association.
A statistically
significant relative
risk of testing
positive for IgA
anti-gliadin antibody
(AGA) in patients
with psoriasis, as
compared to control
subjects (ORtotal =
2.36; 95% C.I. 1.154.83)
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4
Psoriasis
RA
Celiac
Crohn’s

Wu, J.J., Nguyen, T.U., Poon,
K.Y.T., & Herrinton, L.J. (2012).
The association of psoriasis with
autoimmune diseases. Journal of
the American Academy of
Dermatology, 67(5), 924-930.
doi:10.1016/j.jaad.2012.04.039

Retrospective
Cohort study
(with control
group)
Level of
evidence: 2+

A retrospective
cohort study in
order to examine
the association
between
psoriasis and 21
common
autoimmune
diseases that
share common
pathogenetic
mechanisms,
including celiac
disease, Crohn’s

First, diagnostic
information was
culled from
databases and prior
diagnostic codes,
neither of which
were validatable
(information bias).
And due to their
medical issues, the
patients with
psoriasis may have
had more frequent
contact with the

Six studies
demonstrated that
patients with
psoriasis, with either
elevated AGA
and/or tTG, showed
improvement in
psoriatic lesions
after a GFD.
Psoriasis was
positively associated
with 17 of the 21
studied AI diseases,
with 14 of these
associations being
statistically
significant. The
strongest association
was with RA
(OR=3.6; 95% CI
3.4-3.9). Celiac
disease was the third
strongest association

These findings
suggest that
patients with
psoriasis are
more likely than
control subjects
to be given the
diagnosis of an
additional
autoimmune
disease. The
authors conclude
their study by
recommending

disease and RA.
25,341 patients
with psoriatic
disease were
ultimately
matched with
126,705 control
subjects from
KPSC.

123

5
Psoriasis
RA
NOT Crohn’s

Tsai, T.F., Wang, T., Hung, S.,
Tsai, P.I., Schenkel, B., Zhang, M.
& Tang, C. (2011). Epidemiology
and comorbidities of psoriasis
patients in a national database in
Taiwan. Journal of
Dermatological Science, 63, 40-46.
doi:10.1016/j.jdermsci.2011.03.002

Retrospective
Cohort study
(with control
group)
Level of
evidence: 2+

A retrospective
cohort study
(with controls)
was performed
using the
Taiwan National
Health
Insurance
Research
Database
(NHIRD) during
2006. The
authors’ aim
was to study the
prevalence of
comorbidities in
patients with
psoriasis.

health care system
resulting in a
greater opportunity
to record associated
diseases, as
compared to the
control group
(selection bias).
Another limitation
to this study is that
is was limited to the
geographic location
of southern
California.

Possible
information bias,
lack of clinical data
allowing for the
adjustment of
outcomes as related
to potential
confounders
(smoking status or
psychosocial
factor), possible
increased health
care visits for
psoriatic patients
versus the controls,
and geographic
area.

(OR=2.3; 95% CI
1.6-3.2), and
Crohn’s disease was
the fifth strongest
association
(OR=1.8; 95% CI
1.5-2.2).
Individuals with
psoriatic disease
were more like
likely to have at
least two (OR=1.6;
95% CI 1.5-1.7) or
three (OR=1.9; 95%
CI 1.6-2.4) immunemediated diseases
compared to persons
without psoriatic
disease.
Patients with
psoriasis had a total
increased risk for
depression
(RR=1.50; 95% CI
1.39-1.61, p-value
>.0001),
hypertriglyceridemia
(RR=1.61; 95% CI
1.54-1.68, p-value
>.0001),
hypertension
(RR=1.51; 95% CI
1.47-1.56, p-value
>.0001), diabetes
(RR=1.64; 95% CI
1.58-1.70, p-value
>.0001),

that the
evaluation of
patients with
psoriasis for
other
autoimmune
diseases may be
warranted as part
of their medical
care.

Clinicians
should take into
consideration the
association of
co-morbidities
when evaluating
the potential
burdens of
psoriatic patients
and designing
effective health
care
management
plans.

Patients were
identified with
at least one
outpatient visit
or admission
claim with an
ICD-9 diagnosis
for psoriatic
arthropathy
(696.0) or
psoriasis
(696.1),
resulting in a
sample of
51,800 cases.
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The psoriasis
cases were then
further classified
by severity.
Moderate to
severe (sPsO,
n=9,063), mild
psoriasis (mPsO,
n=36,252).
Control group
(n=207,200)
was matched at
a 4:1 ratio based
on age, gender
and residential
area.
Co-morbidities
were defined
based on at least

cardiovascular
disease (RR=1.32;
95% CI 1.26-1.37,
p-value >.0001) and
malignancies of the
digestive organs and
peritoneum
(RR=1.57; 95% CI
1.41-1.74, p-value
>.0001).
Patients with
moderate to severe
psoriasis were found
to have 10.25 times
the risk for RA
(95% CI 8.20-12.81,
p value > .0001),
and patients with
mild psoriasis were
found to have 1.56
the risk for RA
(95% CI 1.33-1.83,
p value > .0001)
compared to patients
without psoriasis.
The total risk for RA
among all patients
with psoriasis was
calculated to be 3.02
times that for nonpsoriatic patients
(95% CI 2.68-3.41,
p value > .0001).
Patients with
Crohn’s disease was

three claims for
an outpatient
visit or one
hospitalization
with a
principal/secondary diagnosis
within one year
of the index
date, 2006 (Tsai
et al., 2011).

actually lower in
this study as
compared to patients
without psoriasis,
although the authors
state that this lower
percentage did not
show statistical
significance.
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The authors
calculated
prevalence
associated with
psoriasis and comorbidities
between cases
and controls
using relative
risk (RRs) and
95% confidence
intervals (CI)
based upon a
Cox
proportional
regression
model.
6
Psoriasis
RA
Crohn’s

Augustin, M., Reich, K., Glaeske,
G., Schaeffer, I. & Radtke, M.
(2010). Co-morbidity and agerelated prevalence of Psoriasis:
Analysis of health insurance data in
Germany. Acta DermatoVenereologica, 90, 147-151. doi:

Retrospective
cohort study
(with control
group)
Level of
evidence: 2+

Evaluation of
the prevalence
of comorbidities in
patients with
psoriasis,
particularly

Possible
information bias,
lack of clinical data
allowing for the
adjustment of
outcomes as related
to potential

Individuals with
psoriasis showed
increased rates of
co-morbidities
compared to
individuals without
psoriasis.

The results of
this study
strongly support
the association
of psoriasis and
systemic chronic
inflammatory

10.2340/00015555-0770

those related to
metabolic
syndrome and
RA and Crohn’s
disease.
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33,981
individuals were
identified for
having psoriasis
and 1,310,090
individuals
without
psoriasis served
as the controls
from a German
nationwide
statutory health
insurance
database.
Prevalences
were calculated
for comorbidities of
interest and the
prevalence ratio
was determined
by comparing
the prevalence
rate of the
psoriatic group
to the nonpsoriatic group.
Corresponding
confidence
intervals were

confounders
(smoking status or
psychosocial
factor), possible
increased health
care visits for
psoriatic patients
versus the controls,
and geographic
area.

diseases.
RA (PR=3.84; 95%
CI 3.43-4.31)
Metabolic syndrome
(PR=2.86; 95% CI
2.21-3.71).
Crohn’s disease
(PR=2.06; 95% CI
1.84-2.31)
Diabetes mellitus
(PR=2.02; 95% CI
1.96-2.08);
hyperlipidemia
(PR=1.75; 95% CI
1.72-1.78);
arterial hypertension
(PR=1.73; 95%
CI1.71-1.76); and
obesity (PR=1.72;
95% CI 1.68-1.76)

These findings
should influence
the healthcare
management of
patients with
psoriasis by
clinicians.

7
Psoriasis
Crohn’s

Makredes, M., Robinson, D., Bala,
M., & Kimball, A.B. (2009). The
burden of autoimmune disease: A
comparison of prevalence ratios in
patients with psoriatic arthritis and
psoriasis. Journal of the American
Academy of Dermatology, 61(3),
405-410.
doi:10.1016/j.jaad.2009.02.015

Retrospective
Cohort study
(with control
group)
Level of
evidence: 2+

127
8
Psoriasis
Celiac

Birkenfeld, S., Dreiher, J.,
Weitzman, D, & Cohen, A.D.
(2009). Coelic disease associated
with psoriasis. British Journal of

Case-Control
study
Level of

computed by a
general method
based on
constant X2
boundaries.
A retrospective
cohort study.
The authors
investigated
whether patients
with psoriatic
arthritis (PsA)
carry a higher
AI disease
burden than
patients with
psoriasis (PsO)
alone. These
authors utilized
the IMS Health
Integrated
Administrative
Claims Database
(Norwalk, CT)
to compare the
prevalence of
seven AI
disorders among
patients with
PsA and PsO,
including
Crohn’s disease
and IBD.
A case-control
study
investigating the
association

Possible
information bias,
lack of clinical data
allowing for the
adjustment of
outcomes as related
to potential
confounders
(smoking status or
psychosocial
factor), possible
increased health
care visits for
psoriatic patients
versus the controls,
and geographic
area.

Patients with PsO
had an increased PR
associated with
Crohn’s disease
(1.6; 95% CI 1.42.0) and
inflammatory bowel
disease (1.4; 95% CI
1.2-1.6) when
compared to
individuals without
psoriasis.

Inability to confirm
patient diagnoses,
either for psoriasis,
CrD and UC.

The prevalence of
CD was greater in
patients with
psoriasis than in

Demonstrating an
even stronger
relationship, patients
with PsA also
carried an increased
risk for Crohn’s
disease (2.1; 95% CI
1.3-3.3) and
inflammatory bowel
disease (1.8; 95% CI
1.3-2.5).

First, the data
supports the
premise that PsA
and PsO are
associated with
the development
of other AI
diseases.
Second, patients
with PsA and
PsO appear to be
at greater risk for
GI diseases.
Third, these
findings suggest
that evaluating
psoriatic patients
in a prospective
manner for other
associated AI
disorders may be
important toward
the patient’s
long-term health
outcomes.

Healthcare
providers should
be aware of the
possible

Dermatology, 161, 1331-1334.
Doi:10.1111/j.13652133.2009.09398.x

evidence: 2+

between
psoriasis and
celiac disease,
via the large
medical dataset
of Clalit Health
Services (CHS).
Patient cases
n=12,502;
cohorts without
psoriasis were
matched by sex
and age, n=
24,285

Misclassification of
information cannot,
therefore, be
completely ruled
out.
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controls. The
association between
psoriasis and CD
was further
evaluated by age,
20-39 years, 40-59
years and 60-110
years. In all age
groups, the
association was
significant, however
the strength of the
association
decreased with
increasing age.
Additionally, an
association was
prominent among
women and among
those of
intermediate SES
(Birkenfeld et al.,
2009).
There were neither
significant
confounding factors
noted among age,
sex or SES, nor
effect modification
by any covariate.
The multivariate
logistic regression
analysis revealed
that psoriasis was
associated with CD
(OR=2.73; 95% CI
1.65-4.53, p-value <

association
between
psoriasis and
CD.
Active screening
for CD may lead
to a diagnosis of
latent CD in
patients with
other
autoimmune
diseases,
particularly in
those with
psoriasis.

0.001). The strength
of the associated
remained significant
after controlling for
age, sex and SES
(OR=1.79; 95% CI
1.03-3.10, p-value =
0.039).
9
Psoriasis
Crohn’s

Li, W-Q., Han, J-L., Chan, A.T. &
Qureshi, A.A. (2013). Psoriasis,
psoriatic arthritis and increased risk
of incident Crohn’s disease in US
women. Annals of the Rheumatic
Diseases, 72, 1200-1205.

Prospective
Cohort study
Level of
evidence: 2+
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A prospective
cohort study
evaluated the
association
between
psoriasis,
psoriatic
arthritis and
incident UC and
CrD among
women in the
US, using two
large, ongoing
prospective
studies of US
women, the
Nurses’ Health
Study (NHS)
and the NHS II.
Statistical
analysis
included (1)
time dependent
Cox
proportional
hazards model
stratified by age

Because the study
was limited to US
female healthcare
workers, additional
research should be
conducted in other
populations to
confirm results.

Women with
psoriasis had an
increased risk of
developing CrD
with a multivariate
adjusted RRs of 4.05
(95% CI 1.75-9.38)
in NHS and 3.76
(95% CI 1.82-7.74)
in NHS II.
The pooled analysis
demonstrated that
psoriasis was
associated with a
RR of 3.86 (95% CI
2.23-6.67) for
developing CrD (Li
et al., 2013).
The authors did not
find a statistically
significant increased
RR for development
of UC in women
with psoriasis in
either database.

These findings
offer additional
evidence in the
support of
common
underlying
mechanisms
between
psoriasis and
CrD.
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Psoriasis
Crohn’s

Cohen, A.D., Dreiher, J. &
Birkenfeld, S. (2009). Psoriasis
associated with ulcerative colitis
and Crohn’s disease. Journal of
the European Academy of
Dermatology and Venereology, 23,
561-565. doi:10.111/j.14683083.2008.03031.x

Case-Control
study
Level of
evidence: 2+

for the
estimation of
relative risks
(RRs) and 95%
CI; (2) multivariate analysis
with adjustments for age,
BMI, smoking,
alcohol intake,
physical
activity, and use
of postmenopausal, oral
contraceptive,
aspirin and
NSAID drugs;
(3) betweenstudies
heterogeneity
and overall
association from
random effects.
Case-control
study
investigating
the relationship
between
psoriasis and the
components of
inflammatory
bowel disease,
UC and CrD,
Utilization of a
large, Israeli
medical dataset
via Clalit Health

Inability to confirm
patient diagnoses,
either for psoriasis,
CrD and UC.
Misclassification of
information cannot,
therefore, be
completely ruled
out.

The prevalence of
both UC and CrD
was significantly
increased in patients
with psoriasis
compared to those
without psoriasis.
The association of
UC and psoriasis
compared with
controls was
statistically
significant in
patients 20-39 years

The findings of
this study cast
additional
support for a
significant
association
between
psoriasis and the
inflammatory
bowel diseases.

Services (CHS).
Patient cases
n=12,502;
cohorts without
psoriasis were
matched by sex
and age, n=
24,285
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old (OR=5.78; 95%
CI 1.81-18.5, pvalue ≤ 0.001), in
male patients
(OR=1.78; 95% CI
1.11-2.82, p-value <
0.05), and in nonsmokers (OR=1.99;
95% CI 1.34-2.95,
p-value ≤ 0.001).
The multivariate
analysis findings
indicate that
ulcerative colitis
was significantly
associated with a codiagnosis for
psoriasis (OR=1.65;
95% CI 1.15-2.33),
as well as with age,
sex and SES of the
patient (Cohen et al.,
2009).
The association of
CrD and psoriasis
compared with
controls
demonstrated
similar, but more
widespread results.
For example, while
UC showed
statistical
significance with
patients aged 20-39
years, CrD was
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associated with
patients in both the
20-39 (OR=6.05;
95% CI 2.91-12.6,
p-value ≤ 0.001) and
40-59 (OR=2.14;
95% CI 1.13-4.05,
p-value < 0.05) age
brackets. A
significant
association was also
found for patients
with psoriasis and
CrD for both
genders, with a
higher burden on
females (OR=4.60;
95% CI 2.50-8.45,
p-value ≤ 0.001)
versus males
(OR=1.66; 95% CI
1.02-2.71, p-value <
0.05), as well as in
smokers (OR=2.78;
95% CI 1.26-6.16,
p-value < 0.05) and
non-smokers
(OR=2.48; 95% CI
1.61-3.80, p-value <
0.05), compared to
controls. The
multivariate analysis
indicates that,
likewise to UC, CrD
is significantly
associated with codisease of psoriasis

(OR=2.49; 95% CI
1.71-3.62, p-value <
0.001), age, sex and
SES (Cohen et al.,
2009).
11
Psoriasis
Crohn’s

Wolf, N., Quaranta, M., Prescott,
J.J., Allen, M., Smith, R., Burden,
A.D., …Trembath, R.C. (2008).
Psoriasis is associated with
pleiotropic susceptibility loci
identified in type II diabetes and
Crohn disease. Journal of Medical
Genetics, 45, 114-116.
doi:10.1136/jmg.2007.053595

Case-Control
study
Level of
evidence: 2+

133

15 CrD
susceptibility
loci newly
identified by
genome-wide
association
analysis were
assessed for
significant
disease
associations
with psoriasis.
A total of 1,256
patients were
included in the
study, 645 male
and 611 female,
all of northern
European
descent and with
onset of
psoriasis
vulgaris
occurring before
40 years of age.
Less than 1% of
the patients also
had documented
CrD. The
patients were

Significant disease
association for three
independent CrD
markers, rs1203582
(p=0.009; OR=1.14;
95% CI 1.03 to
1.25), rs6908425
(p=0.00015;
OR=1.26; 95% CI
1.12 to 1.42) and
rs2836754
(p=0.0003;
OR=1.17; 95% CI
1.06 to 1.30), was
observed among the
psoriasis cases
(Wolf et al, 2008).

Three of the
examined
Crohn’s disease
SNPs are
significantly
associated with
psoriasis.
The results of
this study lend
additional
evidence to
suggest that
individuals with
psoriasis are also
predisposed to
CrD. This
highlights the
pleiotropic
effects of coautoimmunity, in
which one gene
influences two
or more
seemingly
unrelated
phenotypic
traits.

matched with
2,938 controls
from the
Wellcome Trust
Case-Control
Consortium
(WTCCC).
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Celiac

Damasiewicz-Bodzek, A. &
Wielkoszynski, T. (2008).
Serologic markers of celiac disease
in psoriatic patients. Journal of the
European Academy of
Dermatology and Venereology, 22,
1055-1061. doi:10.1111/j.14683083.2008.02713.x

Case-control
study
Level of
evidence: 2+

Patient DNA
was typed using
TaqMan assays
and the
frequencies of
alleles for both
cases and
controls were
compared using
a X2 test with
one degree of
freedom.
Regression
analysis was
conducted with
PLINK
software.
Investigated
whether patients
with psoriasis
also had
increased levels
of CDassociated
antibodies
compared to
healthy controls,
implicating
gluten

5.7% of psoriatic
patients screened
positive for four
serologic markers,
while 28.1% had
three serologic
markers positive,
and 17.7% had two
serologic markers
positive.
By Kolmogorov-

Given the widely
accepted use of
these antibody
tests to diagnose
celiac disease,
these results
suggest that
there is an
association
between
psoriasis and
asymptomatic
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intolerance.
The authors
measured titres
of IgA and IgG
antibodies
against tissue
transglutaminse
from guinea pig
liver (a-GPtTG), of IgA
antibodies
against human
recombinant
tissue
transglutaminase
(a-h-r-tTG IgA),
of anti-gliadin
antibodies
(AGA IgA and
AGA IgG), as
well as antiendomysial
antibodies for
IgA (IgEmA) in
patients with
and without
psoriasis.

Smirnov, U MannWhitney and WaldWolfowitz’s tests,
patients with
psoriasis have
statistically
significant higher
mean levels of
antibodies against
tissue
transglutaminase
from guinea pig
liver (a-GP-tTG) for
both IgA (p <0.001,
P=0.000000 and
p=0.000006,
respectively) and
IgG (p < 0.001,
p=0.000001, and
p=0.01) than do
patients without
psoriasis.
Furthermore, in 46%
of the cases for IgG,
and as much as 66%
of the IgA cases,
titres of antibodies
were higher than the
90th percentile of the
control values.
Patients with
psoriasis also had
higher mean levels
of IgA antibodies
against the human
recombinant tissue
transglutaminase (p

celiac
disease/gluten
intolerance.
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< 0.001, P = 0.036
and p=0.002); 54%
of the cases were
higher than the 90th
percentile of the
control values. The
titres of antibodies
against gliadin
between psoriatics
and controls were
increased at
statistically
significant levels for
IgA (p < 0.001, p =
0.000000 and p =
0.0005), but not for
IgG (p > 0.01, p =
0.75, and p = 0.244).
And no antiendomysial
antibodies for IgA
were found in any
serum, either cases
or controls.
Concentrations of ah-r-tTg IgA
positively correlated
with concentrations
of a-GP-tTG IgA, a
GP-tTg IgG and
AGA IgA.
Concentrations of ah-r-tTG IgA, a-GPtTG IgA and AGA
IgA also positively
correlated with
PASI .

13
Psoriasis
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Celiac

Einarsdottir, E., Koskinen, L.L.E.,
Dukes, E., Kainu, K., Suomela, S.,
Lappalainen, M., …Saavalainen, P.
(2009). IL23R in the Swedish,
Finnish, Hungarian and Italian
populations: association with IBD
and psoriasis, and linkage to celiac
disease. BMC Medical Genetics,
10, 1-10.
doi: 10.1186/1471-2350-10-8

Cross sectional
study
Level of
evidence: 3
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Investigated the
association of
genetic markers
in the
interleukin-23
receptor
(IL23R) gene, as
well as the
intergenic
region between
IL23R and
IL122RB2, with
inflammatory
bowel disease
and psoriasis in
with Swedish
and Finnish
patients with
IBD. Also,
investigated
IL23R’s
association with
celiac disease
among Finnish,
Hungarian, and
Italian
populations.

Underrepresentation
of non-Swedish,
Finnish, Italian,
Hungarian races

SNP rs11465804*G
demonstrated the
strongest association
for the combined
dataset including
both CD and UC
(p=0.002,
OR=0.42). Marker
rs1004819 also
indicated a strong
association with
Crohn’s disease in
the Swedish
population
(p=0.006, OR=1.43)
(Einarsdottir et al.,
2009).
The Finnish families
demonstrated
significant linkage
for celiac disease
(lod=3.24,
p=0.00006, 135
individuals), while
the Hungarian
families did not
(lod=0.4, p=0.08,
132 individuals)
(Einarsdottir et al.,
2009).
Additionally, none
of the celiac disease
case-control datasets
demonstrated
significant
association to any of

1st study to
report
association of
IL23R with
Crohn’s disease
and UC in
Swedish pts with
IBD. Also 1st to
demonstrate
linkage and
association of
the IL23R region
wih psoriasis in
the Finnish
population. Also
reports the novel
finding of
linkage with
IL23R to celiac
disease.

the IL23R markers
Fifty-one of the 255
Finnish families
with psoriasis were
informative for
linkage, yielding a
lod score of 0.83
(p=0.03). However,
despite the low
score, an association
of IL23R with
psoriasis was
confirmed in the
Finnish casecontrols.
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Radtke, M.A., Mrowietz, J.U.,
Feuerhahn, M.H., Von Kiedrowski,
R., Nast, K.R.A., Stromer, J.K. &
Wohlrab, M.A. (2015). Early
detection of comorbidity in
psoriasis: recommendations of the
National Conference on Healthcare
in Psoriasis. Journal of the
German Society of Dermatology,
13(7), 674-90. doi:
10.1111/ddg.12643

Expert opinion
Level of
evidence: 4

A German
interdisciplinary
partnership
whose objective
was to develop
screening
algorithms for
dermatologists
for twelve
different
comorbidities in
patients with
psoriasis,
including
chronic
inflammatory
bowel disease.
First, a national
consensus
conference on

The twelve
comorbidities
chosen for screening
in patients with
psoriasis included
arterial
hypertension,
dyslipidemia,
obesity, diabetes
mellitus, metabolic
syndrome,
nonalcoholic
steatohepatitis,
depression, nicotine
abuse, alcohol
abuse, psoriatic
arthritis, malignant
lymphoma and
chronic
inflammatory bowel

The following
target parameters
for screening
were identified
for IBD.
Chronic diarrhea
(> 3 bowel
movements per
day and > 4
weeks) and ≥ 1
of the following
symptoms:
– Blood in stool
– Pain or
bleeding during
intestinal
peristalsis
– Painful
defecation (DD:
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psoriasis
established a
definition for the
requirements,
areas of
application,
conception, and
methodology of
an agreed
screening
algorithm.
Second, a
literature search
was conducted
to investigate
the most
relevant
comorbidities
associated with
psoriasis, as
well as possible
screening
approaches.
More than 2,000
publications
were included in
the appraisal and
evidence for the
use of screening
parameters for
the individual
comorbidities
was compiled
Finally, an
interdisciplinary
group of the
National

disease.

differentiation
from anal
fissure,
hemorrhoids)
– Abdominal
pain especially
in the right lower
abdomen
– Pyoderma
gangrenosum,
erythema
nodosum, oral
aphthae
– Temperature >
37.8 °C during
the past 7 days
– Weight loss
– Anal fistula,
anal fissures, or
perirectal
abscesses or
other fistulas
(e.g.
enterovesical
fistula)
– Ocular
involvement:
uveitis or iritis
– Arthritis or
arthralgia

Healthcare
Conference
evaluated the
algorithms
according to
content-related,
methodological,
and formal
characteristics,
as well as
practicability.
The algorithms
were then
adopted through
a Delphi
consensus
process.
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Appendix C
Scottish Intercollegiate Guidelines Network (SIGN) Grading System 1999 – 2012:
Grades of Recommendations
A At least one meta-analysis, systematic review, or RCT rated as 1++, and directly
applicable to the target population; or
A body of evidence consisting principally of studies rated as 1+, directly applicable
to the target population, and demonstrating overall consistency of results
B A body of evidence including studies rated as 2++, directly applicable to the target
population, and demonstrating overall consistency of results; or
Extrapolated evidence from studies rated as 1++ or 1+
C A body of evidence including studies rated as 2+, directly applicable to the target
population and demonstrating overall consistency of results; or
Extrapolated evidence from studies rated as 2++
D Evidence level 3 or 4; or
Extrapolated evidence from studies rated as 2+
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Appendix D
Patient Questionnaire
Age: ____________
Gender:
o Male
o Female
1) Do you have a first-degree relative with celiac disease, Crohn’s disease or rheumatoid
arthritis?
o No
o Yes
If you answered yes to the question above, please complete the following:
My mother / father / sister / brother / child has:
o Celiac disease
o Crohn’s disease
o Rheumatoid arthritis
2) Do you have chronic or recurrent diarrhea? (≥ 3 loose stools per day for > 4 weeks)
(CD/CrD)
o No
o Yes
3) Have you been losing weight? (CD/CrD)
o No
o Yes
If yes, how much weight have you lost over the past 6 months? ___________
4) Do you have abdominal pain after eating? (CD/CrD)
o No
o Yes
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If yes, indicate on the diagram below where your pain occurs:

Right
side

Left
side

How would you rate your pain?
0
none

1

2
mild

3

4

5
moderate

6

7

8
very bad

9

10
unbearable

How long does the pain last? __________________
How would you describe the pain?

o throbbing
o shooting
o stabbing
o sharp
o cramping

o gnawing
o burning
o aching
o pressure
o other: _____________

5) Do you suffer from abdominal distention and/or bloating after eating? (CD)
o No
o Yes
6) Is it painful to have a bowel movement? (CrD)
o No
o Yes
7) Have you ever seen blood in your stool? (CrD)
o No
o Yes
8) Have you had a fever in the past 4 weeks? (CrD)
o No
o Yes
If yes, what was your temperature? ___________
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9) Has a health care provider ever told you that you have irritable bowel syndrome?
(CD/CrD)
o No
o Yes
10) Has a health care provider ever told you that you were anemic? (CD/CrD)
o No
o Yes
11) Has a health care provider ever told you that have a vitamin D deficiency? (CD/CrD)
o No
o Yes
12) Has a health care provider ever told you that you have elevated liver enzymes?
(CD/CrD)
o No
o Yes
13) Have you had morning stiffness in any of your joints for > 30 minutes for > 6 weeks?
(RA)
o No
o Yes
If yes, how often do you have morning stiffness > 30 minutes?
o every day
o 1-3 days a week
o 4-6 days a week
Indicate on the diagram below which joints are stiff:
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Right side

Left side

14) Have you had joint or muscle pain on a daily basis for > 6 weeks? (RA)
o No
o Yes
If yes, indicate on the diagram below where your pain is located:

Right side

Left side

How would you rate your pain?
0
none

1

2
mild

3

4

5
moderate
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6

7

8
very bad

9

10
unbearable

How long does the pain last? __________________
How would you describe the pain?
o throbbing
o shooting
o stabbing
o sharp
o cramping

o gnawing
o burning
o aching
o pressure
o other: _____________

15) Have you had any tender or swollen joints on a daily basis for > 6 weeks? (RA)
o No
o Yes
If yes, indicate on the diagram below which joints are tender or swollen:

Right side

Left side

16) Have you had tingling sensations in your hands or feet on a daily basis for > 6
weeks? (CD/RA)
o No
o Yes
17) Have you had weakness or fatigue for > 6 weeks? (RA)
o No
o Yes
If yes, how often do you have weakness or fatigue?
o every day
o 1-3 days a week
o 4-6 days a week
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Appendix E
Referral Algorithm for Celiac Disease
Patient has a 1st degree relative with Celiac disease?
Yes
No
Refer if patient presents with any of the
Refer if patient presents with ≥ 3 of the
following:
following:
- ≥ 3 loose stools per day for > 4
- ≥ 3 loose stools per day for > 4
weeks
weeks
- Abdominal pain after eating
- Abdominal pain after eating
- Abdominal distention/bloating after
- Abdominal distention/bloating after
eating
eating
- Weight loss
- Weight loss
- Has ever been told they have IBS
- Has ever been told they have IBS
- Hx of malabsorption problems
- Hx of malabsorption problems
(anemia, vitamin D deficiency)
(anemia, vitamin D deficiency)
- Hx of elevated liver enzymes
- Hx of elevated liver enzymes
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Appendix F
Referral Algorithm for Crohn’s Disease
Patient has a 1st degree relative with Crohn’s disease?
Yes
No
Refer if patient presents with any of the
Refer if patient presents with ≥ 3 loose
following:
stools per day for > 4 weeks AND ≥ 1 of
the following symptoms:
- ≥3 loose stools per day for > 4
weeks
- Abdominal pain after eating
- Abdominal pain after eating
- Weight loss
- Weight loss
- Painful defecation
- Painful defecation
- Blood in stool
- Blood in stool
- Fever in the last 4 weeks
- Has ever been told they have IBS
- Has ever been told they have IBS
- Hx of malabsorption problems
- Hx of malabsorption problems
(anemia, vitamin D deficiency)
(anemia, vitamin D deficiency)
- Hx of elevated liver enzymes
- Hx of elevated liver enzymes
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Appendix G
Referral Algorithm for Rheumatoid Arthritis
Refer if patient presents with at least 1 joint with clinical synovitis (swelling) for > 6
weeks.
-orRefer if patients presents with ≥ 3 of the following:
- Morning joint stiffness for > 60 minutes for > 6 weeks
- Joint/muscle pain for > 6 weeks
- Tender joints for > 6 weeks
- Tingling sensations in the hands/feet for > 6 weeks
- Weakness/fatigue for > 6 weeks
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Appendix H
Coded Identifier List
Patient Name

Chart Number

Visit Date
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Subject Number

Appendix I
Chart Review – Data Collection Form
Subject #

Psoriasis Questionnaire
completed

Screening
documented

Referral documented

1,2,3…

No=0
Yes=1

No=0
Yes=1

No referral=0
Yes referral=1

No=0
Yes=1
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Appendix J
Screening Questionnaire – Data Collection Form
(Excel columns shown below in vertical format)
Visit
Time
0:00

Age (years)
#

if yes - 1b
CD=0
CrD=1
RA=2

2
No=0
Yes=1

3
No=0
Yes=1

if yes - 4b

if yes 4c (hrs)
#

if yes - 4d

Subject #
1,2,3…

Visit Date
mm/dd/yyyy

if yes - 1a
mother=0
father=1
sister=2
brother=3
child=4
if yes - 4a
RUQ=0
LUQ=1
RLQ=2
LLQ=3

6
No=0
Yes=1

0=0
1=1
2=2
3=3
4=4
5=5
6=6
7=7
8=8
9=9
10=10
7
No=0
Yes=1

11
No=0
Yes=1
if yes - 14a

1
No=0
Yes=1

if "other"
- 4e

5

throbbing=0
shooting=1
stabbing=2
sharp=3
cramping=4
gnawing=5
burning=6
aching=7
pressure=8
other=9

8
No=0
Yes=1

if yes - 8a (°F)
#

12
No=0
Yes=1

13
No=0
Yes=1

if yes - 14b

if yes 14c
(hrs)

if yes - 13a
every day=0
1-2 days/wk=1
4-6 days/wk=2
if yes - 14d
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Gender
male=0
female=1
if yes - 3a
(lbs)
#

4
No=0
Yes=1

No=0
Yes=1

9
No=0
Yes=1
if yes 13b
See
Appendix
K
if "other"
- 14e

10
No=0
Yes=1
14
No=0
Yes=1
15

See Appendix K

0=0
1=1
2=2
3=3
4=4
5=5
6=6
7=7
8=8
9=9
10=10

#

throbbing=0
shooting=1
stabbing=2
sharp=3
cramping=4
gnawing=5
burning=6
aching=7
pressure=8
other=9

if yes - 15a

16

17

If yes - 17a

See Appendix K

No=0
Yes=1

No=0
Yes=1

every day=0
1-2 days/wk=1
4-6 days/wk=2
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No=0
Yes=1

if yes 15a
See
Appendix
K

Referred?
No=0
Yes=1

Appendix K
Key For Questions 13b, 14a and 15a
jaw (right)=0
jaw (left)=1
jaw (bilateral)=2
neck (right)=3
neck (left)=4
neck (bilateral)=5
shoulder (right)=6
shoulder (left)=7
shoulder (bilateral)=8
elbow (right)=9
elbow (left)=10
elbow (bilateral)=11
wrist (right)=12
wrist (left)=13
wrist (bilateral)=14
hand (right)=15
hand (left)=16
hand (bilateral)=17
thumb (right)=18
pointer finger (right)=19
middle finger (right)=20
ring finger (right)=21
pinky finger (right)=22
thumb (left)=23
pointer (left)=24
middle finger (left)=25
ring finger (left)=26
pinky finger (left)=27
thumb (bilateral)=28

pointer (bilateral)=29
middle finger (bilateral)=30
ring finger (bilateral)=31
pinky finger (bilateral)=32
hip (right)=33
hip (left)=33
hip (bilateral)=34
knee (right)=35
knee (left)=36
knee (bilateral)=37
ankle (right)=38
ankle (left)=39
ankle (bilateral)=40
great toe (right)=41
second toe(right)=42
third toe (right)=43
fourth toe (right)=44
fifth toe (right)=45
great toe (left)=46
second toe (left)=47
third toe (left)=48
fourth toe (left)=49
fifth toe (left)=50
great toe (bilateral)=51
second toe (bilateral)=52
third toe (bilateral)=53
fourth toe (bilateral)=54
fifth toe (bilateral)=55
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Appendix L
IRB Approval
NOT HUMAN SUBJECT RESEARCH
ID:
Title:
PI:
Study Title:
Description:

Pro00066977
Not Human Subjects Research
Susan Ashbaugh
Best Practice for Screening Adult Patients with Psoriasis for
Polyautoimmunity: Celiac Disease, Rheumatoid Arthritis and Crohn's
Disease
A study application has been confirmed to be not human subject
research. To navigate to the project workspace, click on the above ID.
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